Design and Discovery of Functionally Selective Serotonin 2C (5-HT$_{2C}$) Receptor Agonists

Jianjun Cheng,[†,∥,⊥] John D. McCorvy,[‡,∥] Patrick M. Giguere,[‡,∥,#] Hu Zhu,[‡,▽] Terry Kenakin,[§] Bryan L. Roth,[*,‡] and Alan P. Kozikowski[*,†]

[†]Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States

[‡]National Institute of Mental Health Psychoactive Drug Screening Program, and [§]Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina 27599, United States

ABSTRACT: On the basis of the structural similarity of our previous 5-HT$_{2C}$ agonists with the melatonin receptor agonist tasimelteon and the putative biological cross-talk between serotonergic and melatonergic systems, a series of new (2,3-dihydro)benzofuran-based compounds were designed and synthesized. The compounds were evaluated for their selectivity toward 5-HT$_{2A}$, 5-HT$_{2B}$, and 5-HT$_{2C}$ receptors in the calcium flux assay with the ultimate goal to generate selective 5-HT$_{2C}$ agonists. Selected compounds were studied for their functional selectivity by comparing their transduction efficiency at the G protein signaling pathway versus β-arrestin recruitment. The most functionally selective compound (+)-**7e** produced weak β-arrestin recruitment and also demonstrated less receptor desensitization compared to serotonin in both calcium flux and phosphoinositide (PI) hydrolysis assays. We report for the first time that selective 5-HT$_{2C}$ agonists possessing weak β-arrestin recruitment can produce distinct receptor desensitization properties.



INTRODUCTION

The serotonin 2C (5-HT$_{2C}$) receptor has been found to be an invaluable drug target for a variety of central nervous system (CNS) disorders, such as obesity, schizophrenia, and drug addiction.[1−3] The 5-HT$_{2C}$ receptor is activated endogenously by serotonin (5-HT, **1**, Figure 1), which is a major neurotransmitter widely found in both the periphery and the CNS.[4] The 5-HT$_{2C}$ receptor belongs to the family of serotonin receptors comprising 14 subtypes (5-HT$_{1-7}$, some of these with further subclassifications).[5] All serotonin receptors belong to the G protein-coupled receptor (GPCR) superfamily except 5-HT$_3$, which is a ligand-gated ion channel. The 5-HT$_{2C}$ receptor shares high sequence similarity with the other 5-HT$_2$-family receptors: 5-HT$_{2A}$ and 5-HT$_{2B}$ receptors (55% and 52% homology, respectively).

In the mammalian pineal gland, serotonin can be converted to melatonin (**2**), which is another neurotransmitter that is involved in the control of circadian rhythms linked to certain physiological functions including the timing of sleep, blood pressure regulation, seasonal reproduction, immune function, etc.[6] A close interrelationship between the melatonergic and serotonergic systems has long been suspected, and evidence for their cross-talk has been recently reported. For example, melatonin inhibits the ability of serotonin to phase-shift the suprachiasmatic circadian clock.[7] In fact, agomelatine, which is on the market for major depressive disorder, exhibits melatonin receptor agonist activity as well as 5-HT$_{2C}$ antagonism.[8]

In our previous work, we identified compounds **3** and **4** as highly selective 5-HT$_{2C}$ agonists (Figure 1).[9,10] Both compounds display excellent selectivity against the 5-HT$_{2A}$ and 5-HT$_{2B}$ receptors, whose activation is associated with hallucinogenic effects and cardiac valvulopathy, respectively.[11−13] Interestingly, although compounds **3** and **4** evolved from a hit compound that was identified through a high throughput screening (HTS) campaign,[14] they share the same 2-arylcyclopropylmethylamine backbone with tasimelteon (**5**), a melatonin receptor agonist that was approved recently for the treatment of non-24-h sleep−wake disorder.[15] The cross-talk between melatonergic and serotonergic signaling pathways, and the structural similarity between compounds **3**, **4**, and tasimelteon, thus inspired us to design compounds possessing the general structure **6** (Figure 1). As a matter of fact, both benzofuran and 2,3-dihydrobenzofuran have been reported as substructures of 5-HT$_{2A/2C}$ receptor ligands previously.[16] We anticipated that compound **6** and its analogs **7** and **8** would function as 5-HT$_{2C}$ agonists.

Furthermore, functional selectivity, also known as ligand bias, is a phenomenon whereby a ligand can possess multiple

Received: August 10, 2016
Published: October 11, 2016



Figure 1. Bioinspired design of 2,3-dihydrobenzofuran (**6**) and benzofuran (**7** and **8**) compounds as 5-HT_{2C} agonists.

Scheme 1. Synthesis of Aldehydes 15a−c[a]



[a]Reagents and conditions: (a) Ag_2O, $MgSO_4$, Et_2O, rt, 3 h; (b) butyl vinyl ether, toluene, 50 °C, overnight; then TFA, 50 °C, 3 h, 52% for 2 steps; (c) MeI, K_2CO_3, DMF, rt, 3 h, 96%; (d) H_2 (50 psi), 10% Pd/C, MeOH, overnight, 79%; (e) $LiAlH_4$, THF, 0 °C to rt, 1 h, 93−95%; (f) DMSO, $(COCl)_2$, DCM, −78 °C, 45 min; then Et_3N, 75−89%; (g) DMF, TBSCl, imidazole, rt, 2 h; (h) *n*-BuLi, EtI, THF, −78 °C to rt, 24 h, 94% for 2 steps; (i) TBAF, THF, rt, 1 h, 90%.

receptor signaling events (i.e., G_q-linked calcium flux, β-arrestin recruitment) and is thought to occur through a ligand's ability to stabilize certain receptor conformations.[17] Biased ligands and functional selectivity have emerged as improved therapeutics for several GPCRs including the dopamine D_2 receptor,[18] the κ opioid receptor,[19] and the μ opioid receptor,[20] and it is likely that the interest in the discovery of novel GPCR ligands targeting specific downstream pathways will continue to grow with time. Although functional selectivity has been actively investigated for several GPCRs, especially for 5-HT receptors,[21] there has been little characterization of biased agonism at the 5-HT_{2C} receptor, especially examining β-arrestin recruitment. The recruitment of β-arrestin to GPCRs leads to G-protein-independent signaling, desensitization, and sequestration of the receptor and eventually to GPCR internalization, and it is considered to be an opposing and complementary signaling pathway to G protein signaling.[22] In this article, we report our recent work in synthesizing compounds bearing the general structures **6**−**8**, their pharmacological profiling at 5-HT_{2C}, 5-HT_{2A}, and 5-HT_{2B} receptors and explore for the first time their G protein versus β-arrestin signaling profiles.

RESULTS AND DISCUSSION

Chemistry. We have previously developed a general synthetic approach to various 2-phenylcyclopropylmethylamines,[9,23−25] which employs appropriate benzaldehydes as the starting materials. Hence, the corresponding aldehydes **15a−c** for compounds **6**, **7**, and **8** were prepared and the

Scheme 2. Synthesis of Compounds 6a–8a[a]



[a]Reagents and conditions: (a) $Ph_3P{=}CHC(O)N(OMe)Me$, CH_2Cl_2, rt, overnight, 79–96%; (b) trimethylsulfoxonium iodide, NaH, DMSO, rt, overnight, 83–91%; (c) DIBAL-H, THF, −78 °C, 3 h; then MeOH, $NaBH_4$, rt, 0.5 h, 76–90%; (d) phthalimide, Ph_3P, diethyl azodicarboxylate, rt, overnight, 92–97%; (e) N_2H_4–H_2O, EtOH, reflux, 2 h; then DCM, Et_3N, Boc_2O, rt, 30 min, 70–88%; (f) chiral preparative HPLC; then 2 M HCl in Et_2O, rt, 24–48h, 67–75% (compounds (−)-**6a** and (+)-**6a** were further purified using preparative HPLC and obtained as TFA salts).

Scheme 3. Synthesis of Compounds 6b–f[a]



[a]Reagents and conditions: (a) CH_2Cl_2, BBr_3, −78 °C to rt, 3 h; then Et_3N, Boc_2O, rt, 0.5 h, 90%; (b) R^1X (X = Br or I), Cs_2CO_3, DMF for **26a–d**, 59–94%; 2-fluoroethanol, Ph_3P, diethyl azodicarboxylate, THF for **26e**, 19%; (c) 2 M HCl in Et_2O, rt, 24–48 h, 62–84%.

synthetic routes are depicted in Scheme 1. Methyl 2,5-dihydroxybenzoate **9** was used as the starting material, the oxidation of which with Ag_2O provided quinone **10**. The benzofuran intermediate **11** was prepared via a [3 + 2] cycloaddition of quinone **10** with butyl vinyl ether followed by an aromatization reaction under acidic conditions.[26] The phenol **11** was methylated to afford compound **12**, which was then reduced by hydrogenation to provide the 2,3-dihydrobenzofuran intermediate **13**. This carboxylic ester was converted to aldehyde **15a** via a $LiAlH_4$ reduction followed by a Swern oxidation. By omitting the hydrogenation step, direct $LiAlH_4$ reduction and Swern oxidation of **12** provided **15b** in good yields. To incorporate the ethyl substitution at position 2 of the benzofuran scaffold, the benzyl alcohol **16** was protected as the TBS ether **17**, which was treated in turn with *n*-BuLi and

Scheme 4. Synthesis of Compounds 7b–i[a]



[a]Reagents and conditions: (a) CH_2Cl_2, BBr_3, −78 °C to rt, 3 h; then Et_3N, Boc_2O, rt, 0.5 h, 77%; (b) 2-fluoroethanol, Ph_3P, diethyl azodicarboxylate, THF for **28d**, 99%; R^2X (X = Cl, Br, or I), Cs_2CO_3, DMF for others, 74–95%; (c) 2 M HCl in Et_2O, rt, 24–48h, 57–70%.

Scheme 5. Synthesis of Compounds 8b–f[a]



[a]Reagents and conditions: (a) CH_2Cl_2, BBr_3, −78 °C to rt, 3 h; then Et_3N, Boc_2O, rt, 0.5 h, 86%; (b) 2-fluoroethanol, Ph_3P, diethyl azodicarboxylate, THF for **30c**, 91%; R^3X (X = Br or I), Cs_2CO_3, DMF for others, 94–100%; (c) 2 M HCl in Et_2O, rt, 24–48h, 60–85%.

EtI to provide intermediate **18**.[27] Desilylation and Swern oxidation of **18** produced aldehyde **15c**.

With aldehydes **15a–c** in hand, the syntheses of the desired target compounds **6a–8a** were accomplished following the same approach as we reported previously,[25] as depicted in Scheme 2. Wittig reaction of aldehydes **15a–c** with the commercial reagent *N*-methoxy-*N*-methyl(triphenylphosphoranylidene)acetamide provided acrylamides **20a–c** as their *E* isomers with complete selectivity. Corey–Chaykovski cyclopropanation of **20a–c** generated the cyclopropanes **21a–c** in their *trans* conformations, using the sulfur ylide generated from trimethylsulfoxonium iodide upon treatment with sodium hydride. Next, sequential reduction with DIBAL-H and sodium borohydride provided alcohols **22a–c** in good yields, which were then converted by Mitsunobu reaction with phthalimide to afford the Gabriel imides **23a–c** in excellent yields.

Scheme 6. Camphorsultam-Directed Asymmetric Synthesis of Compound (+)-6d[a]



[a]Reagents and conditions: (a) malonic acid, pyrrolidine, pyridine, reflux, 2 h, 94%; (b) $SOCl_2$, rt, 2 h; then (1*R*)-(+)-2,10-camphorsultam, NaH, THF, 0 °C to rt, overnight, 90%; (c) diazomethane, $Pd(OAc)_2$, CH_2Cl_2/Et_2O, 0 °C to rt, overnight, 58%; (d) LiOH, H_2O/THF, 50 °C, 3 h, 100%; (e) $SOCl_2$, toluene, 80 °C, 2 h; then NH_4OH (28%), 1,4-dioxane, 0 °C to rt, 0.5 h, 98%; (f) BH_3–THF (1.0 M in THF), THF, reflux, 4 h; then Boc_2O, Et_3N, CH_2Cl_2, rt, 0.5 h, 74%; (g) BBr_3, CH_2Cl_2, −78 °C to rt, 3 h; then Boc_2O, Et_3N, rt, 0.5 h, 95%; (h) allyl bromide, Cs_2CO_3, DMF, microwave, 80 °C, 0.5 h, 83%; (i) 2 M HCl in Et_2O, rt, 48 h, 74%.

Deprotection of the imides with hydrazine hydrate afforded the primary amines, which were then protected as the Boc intermediates **24a–c**. Separation of **24a–c** using chiral preparative-HPLC followed by the removal of the Boc group provided compounds (−)-**6a**, (+)-**6a**, (−)-**7a**, (+)-**7a**, (−)-**8a**, and (+)-**8a** as the optically pure isomers.

Preparation of the compounds bearing a 5-alkoxy group other than methoxy was accomplished by demethylation of intermediates **24a–c** followed by alkylation with the appropriate alkyl halides. The syntheses of these compounds are outlined in Schemes 3–5, respectively. The demethylation and alkylation conditions are similar to those we had previously reported for the 2-phenylcyclopropylmethylamines.[25] Notably, chiral separation of the 2,3-dihydrobenzofurans was accomplished using the phenol intermediate **25**, while for the benzofuran and 2-ethylbenzofuran compounds the chiral separation was carried out with the ethers **28a–h** and **30a–e**. These protocols were used due to the fact that chiral separation of intermediates **26a–e** proved very difficult using the chiral columns we had available. Therefore, the resolution was performed one step earlier and the phenol intermediate **25** was separated efficiently with a RegisPack column. Similarly, the final compounds were obtained by removal of the Boc protecting group using HCl in diethyl ether.

In our previous work, the absolute configurations of both enantiomers of 2-phenylcyclopropylmethylamine were assigned by comparison of the optical rotations of their synthetic intermediates to those of known compounds.[14] On the basis of that, we subsequently assigned the absolute configurations of other analogs (which possess an extra 2-alkoxy substitution on the benzene ring) based on the very good correlation of compound potency with the direction of their optical rotations (namely, the (+)-enantiomer is always more potent than the (−)-enantiomer).[9,14,25] Therefore, we assume that an enantiomer with a negative optical rotation possesses the 1*R*,2*R*-configuration, while a compound showing a positive optical rotation has the 1*S*,2*S*-configuration. An X-ray crystal structure would be an ideal way to test whether this is correct. However, for the new compounds described in this work, we have failed to obtain single crystals for X-ray diffraction. An alternative way to address this problem is to use a well-proven asymmetric synthesis method to prepare a representative compound in the series and then to compare its optical rotation with that of the equivalent compound obtained from chiral HPLC separation. Since chiral separation in the 2,3-dihydrobenzofuran series was found to be relatively difficult, we chose compound (+)-**6d** as a representative compound to test this approach.

A camphorsultam-directed asymmetric cyclopropanation reaction,[28–30] for which the absolute configuration of the dominant product could be readily predicted, was used as the key step for the asymmetric synthesis of compound (+)-**6d**. As shown in Scheme 6 (see Supporting Information for experimental details), aldehyde **15a** obtained as described in Scheme 1 was converted to the cinnamic acid **31** through Knoevenagel condensation with malonic acid, followed by the coupling with (1*R*)-(+)-2,10-camphorsultam to produce cinnamamide **32**. The cyclopropanation of substrate **32** would favor a desired inward attack on the double bond. Twenty equivalents of diazomethane was used in this reaction to achieve a greater than 95% conversion of the cinnamamide, and the reaction proceeded in a 96.5/3.5 diastereoselectivity based on HPLC analysis of the crude product. Recrystallization of the crude product from ethanol afforded compound **33** with greater than 99% de purity and 58% yield. The higher diastereoselectivity of this reaction compared to other reported examples (which are mostly below 10:1)[28,29] is possibly due to the di-ortho-substitution pattern of substrate **32**, which would force a higher π-face selectivity. Subsequent hydrolysis of **33** with a solution of lithium hydroxide provided acid **34** in quantitative yield, which was then converted to the corresponding amide **35** in excellent yield. Reduction of **35** was brought about using borane, which was followed by Boc

Table 1. Pharmacological Profiling of Compounds (−)-/(+)-6a−6f, (−)-/(+)-7a−7i, and (−)-/(+)-8a−8f at 5-HT$_2$ Receptors in Calcium Flux Assay[a]

STRUCTURE	ID	h5-HT$_{2C}$				h5-HT$_{2B}$				h5-HT$_{2A}$			
		pEC$_{50}$	EC$_{50}$ (nM)	E$_{max}$ (%5-HT)	Log(E$_{max}$ / EC$_{50}$)	pEC$_{50}$	EC$_{50}$ (nM)	E$_{max}$ (%5-HT)	Log(E$_{max}$ / EC$_{50}$)	pEC$_{50}$	EC$_{50}$ (nM)	E$_{max}$ (%5-HT)	Log(E$_{max}$ / EC$_{50}$)
-	serotonin	9.78 ± 0.02	0.17	100 ± 0.5	9.77	8.84 ± 0.03	1.46	100 ± 1.1	8.84	8.63 ± 0.02	2.35	100 ± 0.7	8.63
-	lorcaserin	8.58 ± 0.01	2.64	100 ± 0.7	8.58	6.36 ± 0.03	433	80 ± 1.6	6.27	6.61 ± 0.01	248	68 ± 0.5	6.44
	(−)-**6a**	7.71 ± 0.02	19	102 ± 1.1	7.73	6.56 ± 0.02	279	45 ± 0.6	6.21	6.53 ± 0.01	295	66 ± 0.7	6.35
	(+)-**6a**	8.05 ± 0.02	8.9	101 ± 0.8	8.05	7.12 ± 0.01	77	70 ± 0.5	6.96	6.93 ± 0.02	117	90 ± 0.9	6.89
	(−)-**6b**	7.39 ± 0.01	41	105 ± 0.6	7.41	6.11 ± 0.03	781	30 ± 0.8	5.58	6.01 ± 0.02	976	35 ± 0.6	5.55
	(+)-**6b**	8.57 ± 0.01	2.7	106 ± 0.7	8.59	7.23 ± 0.02	54	58 ± 0.6	7.03	6.95 ± 0.02	113	81 ± 1.0	6.86
	(−)-**6c**	7.02 ± 0.01	96	94 ± 0.7	6.99	NA	NA	NA	NA	NA	NA	NA	NA
	(+)-**6c**	7.69 ± 0.01	20	104 ± 0.6	7.72	6.59 ± 0.03	258	31 ± 0.5	6.08	6.13 ± 0.01	749	31 ± 0.3	5.62
	(−)-**6d**	7.03 ± 0.01	94	90 ± 0.8	6.98	NA	NA	NA	NA	NA	NA	NA	NA
	(+)-**6d**	7.96 ± 0.01	11	101 ± 0.7	7.96	6.59 ± 0.03	258	35 ± 0.7	6.13	6.20 ± 0.06	618	49 ± 0.7	5.90
	(−)-**6e**	6.55 ± 0.02	283	65 ± 1.0	6.36	NA	NA	NA	NA	NA	NA	NA	NA
	(+)-**6e**	7.58 ± 0.01	26	95 ± 0.7	7.56	6.57 ± 0.05	269	33 ± 1.0	6.09	6.12 ± 0.04	754	17 ± 0.5	5.35
	(−)-**6f**	6.52±0.04	302	79±3.7	6.42	NA	NA	NA	NA	5.71±0.08	1960	55±4.3	5.45
	(+)-**6f**	7.13±0.03	73	76±3.4	7.02	NA	NA	NA	NA	5.63±0.09	2320	63±4.5	5.43
	(−)-**7a**	8.17 ± 0.02	6.6	96 ± 0.9	8.16	6.14 ± 0.18	725	55 ± 8.8	5.88	6.96 ± 0.02	109	66 ± 0.6	6.78
	(+)-**7a**	8.79 ± 0.03	1.6	93 ± 0.9	8.76	6.96 ± 0.12	111	64 ± 5.12	6.76	7.43 ± 0.02	37	86 ± 1.0	7.37
	(−)-**7b**	7.59 ± 0.02	26	107 ± 1.2	7.61	NA	NA	NA	NA	6.23 ± 0.02	585	15 ± 0.2	5.41
	(+)-**7b**	8.59 ± 0.01	2.6	106 ± 0.7	8.61	7.07 ± 0.03	84	50 ± 0.8	6.77	6.96 ± 0.02	111	74 ± 1.0	6.82
	(−)-**7c**	7.06 ± 0.02	87	88 ± 1.1	7.00	NA	NA	NA	NA	NA	NA	NA	NA
	(+)-**7c**	7.99 ± 0.02	10	98 ± 1.1	7.99	NA	NA	NA	NA	6.41 ± 0.02	392	21 ± 0.3	5.73
	(−)-**7d**	7.25 ± 0.01	56	101 ± 0.9	7.26	NA	NA	NA	NA	NA	NA	NA	NA
	(+)-**7d**	8.27 ± 0.03	5.3	103 ± 1.6	8.29	6.46 ± 0.06	348	31 ± 1.1	5.95	6.67 ± 0.02	213	46 ± 0.8	6.33
	(−)-**7e**	7.50 ± 0.02	33	98 ± 1.1	7.47	6.35 ± 0.04	448	34 ± 0.9	5.88	6.41 ± 0.02	393	22 ± 0.4	5.75
	(+)-**7e**	9.22 ± 0.05	0.59	97 ± 1.5	9.22	7.34 ± 0.06	46	103 ± 2.8	7.35	7.65 ± 0.05	22	98 ± 1.8	7.65
	(−)-**7f**	6.95 ± 0.01	113	87 ± 0.8	6.89	6.29 ± 0.06	524	27 ± 1.2	5.71	NA	NA	NA	NA
	(+)-**7f**	7.91 ± 0.01	12	99 ± 0.8	7.92	6.47 ± 0.05	180	27 ± 0.8	6.18	6.34 ± 0.03	456	25 ± 0.6	5.74
	(−)-**7g**	7.67 ± 0.02	21	97 ± 1.0	7.66	6.34 ± 0.24	453	25 ± 4.2	5.74	6.03 ± 0.11	938	38 ± 3.8	5.61
	(+)-**7g**	8.21 ± 0.01	6.2	99 ± 0.6	8.20	6.76 ± 0.04	174	39 ± 1.0	6.35	6.53 ± 0.03	298	79 ± 1.4	6.42
	(−)-**7h**	7.00 ± 0.01	99	93 ± 0.8	6.97	6.23 ± 0.05	585	29 ± 1.2	5.70	NA	NA	NA	NA
	(+)-**7h**	8.03 ± 0.01	9.2	103 ± 0.8	8.05	6.89 ± 0.03	128	38 ± 0.6	6.47	6.45 ± 0.02	358	49 ± 0.7	6.14
	(−)-**7i**	6.58 ± 0.03	261	70 ± 0.9	6.43	6.14 ± 0.07	733	33 ± 1.7	5.65	NA	NA	NA	NA
	(+)-**7i**	7.60 ± 0.02	25	99 ± 0.9	7.60	6.82 ± 0.03	150	40 ± 0.6	6.43	6.59 ± 0.02	260	19 ± 0.3	5.86

Table 1. continued

STRUCTURE	ID	h5-HT$_{2C}$				h5-HT$_{2B}$				h5-HT$_{2A}$			
		pEC$_{50}$	EC$_{50}$ (nM)	E$_{max}$ (%5-HT)	Log(E$_{max}$ / EC$_{50}$)	pEC$_{50}$	EC$_{50}$ (nM)	E$_{max}$ (%5-HT)	Log(E$_{max}$ / EC$_{50}$)	pEC$_{50}$	EC$_{50}$ (nM)	E$_{max}$ (%5-HT)	Log(E$_{max}$ / EC$_{50}$)
	(−)-**8a**	6.99 ± 0.01	101	88 ± 0.7	6.94	NA	NA	NA	NA	NA	NA	NA	NA
	(+)-**8a**	8.57 ± 0.02	2.7	101 ± 1.0	8.57	7.22 ± 0.03	60	55 ± 0.7	6.96	6.03 ± 0.02	939	72 ± 1.6	5.88
	(−)-**8b**	6.94 ± 0.01	115	76 ± 0.8	6.82	NA	NA	NA	NA	NA	NA	NA	NA
	(+)-**8b**	7.84 ± 0.02	15	100 ± 0.8	7.82	6.51 ± 0.04	309	36 ± 0.9	6.07	5.58 ± 0.01	2598	35 ± 0.5	5.13
	(−)-**8c**	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	(+)-**8c**	7.09 ± 0.01	81	96 ± 0.6	7.07	NA	NA	NA	NA	NA	NA	NA	NA
	(−)-**8d**	7.09 ± 0.01	81	84 ± 1.7	7.02	NA	NA	NA	NA	NA	NA	NA	NA
	(+)-**8d**	7.96 ± 0.01	11	106 ± 0.9	7.98	6.26 ± 0.19	550	27 ± 3.7	5.69	5.66 ± 0.04	2210	44 ± 2.0	5.30
	(−)-**8e**	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	(+)-**8e**	7.65 ± 0.02	23	102 ± 0.9	7.65	6.36 ± 0.15	433	19 ± 2.1	5.64	NA	NA	NA	NA
	(−)-**8f**	6.35 ± 0.02	446	69 ± 1.0	6.19	NA	NA	NA	NA	NA	NA	NA	NA
	(+)-**8f**	6.86 ± 0.01	138	101 ± 0.6	6.86	NA	NA	NA	NA	NA	NA	NA	NA

[a]All new compounds were tested as HCl salts except compounds (−)-**6a** and (+)-**6a**, which are TFA salts. Pharmacological data were acquired with recombinant, stably expressed human 5-HT$_{2C}$, 5-HT$_{2A}$, and 5-HT$_{2B}$ receptors in the HEK-293 cell line, using a fluorescence imaging plate reader (FLIPR) assay. pEC$_{50}$ and E_{max} values are shown as the mean ± SEM ($n \geq 2$). EC$_{50}$ values were calculated from averaged pEC$_{50}$ values. "NA" indicates no activity up to 10 μM. "−" indicates structures of serotonin and lorcaserin are not shown.

protection of the free amine to provide intermediate **36**. Demethylation of **36** using BBr_3 afforded the phenol **37**, which was subjected to the same allylation and deprotection procedures as described in Scheme 2 to provide compound **39**. The spectral data and optical rotation value of **39** were in agreement with those of (+)-**6d** which was obtained from chiral HPLC separation. This result would thus confirm that the absolute configuration of (+)-enantiomers is (*S*,*S*) and that of (−)-enantiomers is (*R*,*R*). On the basis of this result, we thus assume that the absolute configurations of compounds (−)-**6a**−**f**, (−)-**7a**−**i**, and (−)-**8a**−**f** are (*R*,*R*) while those of compounds (+)-**6a**−**f**, (+)-**7a**−**i**, and (+)-**8a**−**f** are (*S*,*S*).

Pharmacology. *5-HT$_2$ Receptor Screening.* All new compounds were screened employing recombinant, stably expressed human 5-HT$_{2A}$, 5-HT$_{2B}$, and 5-HT$_{2C}$ receptors in the HEK-293 cell line, using a fluorescence imaging plate reader (FLIPR) assay as we described previously.[9,25] Estimates of E_{max}, EC$_{50}$, and log(E_{max}/EC$_{50}$), which is a relative activity calculation to account for partial agonist differences, are found in Table 1. Serotonin was used as a positive control, and its E_{max} values were normalized to 100% for all receptors. The FDA approved 5-HT$_{2C}$ agonist lorcaserin (EC$_{50}$ = 2.64 nM, E_{max} = 100%, log(E_{max}/EC$_{50}$) = 8.58), used as a reference compound for comparison purposes.

As can be seen from Table 1, most of the new compounds show potent agonism of the 5-HT$_{2C}$ receptor and display selectivity against the 5-HT$_{2A}$ and 5-HT$_{2B}$ receptors. Overall the (+)-isomers are more potent than their (−)-isomers within each pair of enantiomers, and increasing the size of the alkoxyl group at position 5 of the 2,3-dihydrobenzofuran or benzofuran scaffold decreases potency in most cases, while enhancing compound selectivity for the 5-HT$_{2C}$ receptor. These observations are consistent with our previous findings.[9,25] For compounds **6a**−**f** which bear the 2,3-dihydrobenzofuran scaffold **6**, ethoxy substitution provides the best potency (compound (+)-**6b**: EC$_{50}$ = 2.7 nM, E_{max} = 106%, log(E_{max}/EC$_{50}$) = 8.59), whereas the elongation of carbon chain leads to a significant loss of potency as exemplified by compound (+)-**6c** (EC$_{50}$ = 20 nM). Maintaining the four-atom length of the alkoxy chain, allyloxy substitution in compound (+)-**6d** (EC$_{50}$ = 11 nM) increases compound potency while cyclopropylmethyoxy slightly decreases the activity (compound (+)-**6e**, EC$_{50}$ = 26 nM). The presence of a 2-fluoroethoxy substituent as in compound (+)-**6f** results in a reduction in potency at the 5-HT$_{2C}$ receptors (EC$_{50}$ = 73 nM), but a gain of selectivity against the 5-HT$_{2B}$ receptors was achieved as (+)-**6f** shows no 5-HT$_{2B}$ activation at concentrations up to 10 μM.

Changing from the 2,3-dihydrobenzofuran backbone to benzofuran leads to an overall enhancement of 5-HT$_{2C}$ potency, as observed for compounds **7a**−**i**. Compared to compound (+)-**6a**, (+)-**7a** shows improved potency at 5-HT$_{2C}$ (EC$_{50}$ = 1.6 nM, E_{max} = 93%) as well as better selectivity against 5-HT$_{2B}$ (111/1.6 = 69-fold) and 5-HT$_{2A}$ (37/1.6 = 23-fold). For the propyl compound **7c**, the (+)-enantiomer shows 10 nM potency at 5-HT$_{2C}$ receptors, no activity at 5-HT$_{2B}$, and good selectivity against 5-HT$_{2A}$ (EC$_{50}$ = 392 nM). Compared to lorcaserin, (+)-**7c** represents one of the best ligands in this series of compounds in terms of both potency and selectivity. Our efforts in introducing other alkoxy substitutions as shown for compounds **7d**−**i** did not lead to any significant improvements in selectivity as compared to compound (+)-**7c**, but the majority of these compounds showed high potency and moderate selectivity. Compound (+)-**7e**, which bears the 2-fluoroethoxy substitution, displays the best potency among all compounds (EC$_{50}$ = 0.59 nM).

Table 2. Assessment of Functional Selectivity for 5-HT$_{2C}$-Selective Compounds[a]

	Gq calcium flux				β-arrestin-2					
compd	pEC$_{50}$	EC$_{50}$ (nM)	E_{max} (%5-HT)	log(E_{max}/EC$_{50}$)	pEC$_{50}$	EC$_{50}$ (nM)	E_{max} (%5-HT)	log(E_{max}/EC$_{50}$)	bias factor, Gq	bias factor, β-Arr
lorcaserin (ref)	8.46 ± 0.03	3.4	96 ± 1.1	8.45	7.23 ± 0.03	59	91 ± 1.2	7.19	1.0	1.0
5-HT	9.87 ± 0.03	0.14	100 ± 0.8	9.85	7.66 ± 0.02	21	100 ± 1.0	7.68	8.2	0.12
Ro 60-0175	8.65 ± 0.04	2.2	99 ± 1.2	8.65	7.97 ± 0.04	10	87 ± 1.2	7.94	0.3	3.3
(+)-**6d**	7.58 ± 0.03	26	93 ± 1.2	7.55	6.57 ± 0.06	267	35 ± 1.0	6.12	1.5	0.7
(+)-**6f**	7.39 ± 0.03	41	93 ± 1.3	7.36	6.49 ± 0.04	318	42 ± 0.8	6.12	0.9	1.1
(+)-**7d**	8.06 ± 0.04	8.7	92 ± 1.3	8.02	7.71 ± 0.01	20	25 ± 0.9	7.10	0.5	2.0
(+)-**7e**	8.92 ± 0.03	1.2	94 ± 0.8	8.89	7.60 ± 0.06	25	28 ± 0.7	7.05	3.8	0.3
(+)-**8d**	7.65 ± 0.04	22	93 ± 1.3	7.63	7.02 ± 0.04	96	50 ± 1.0	6.72	0.4	2.5
(+)-**8e**	7.60 ± 0.04	25	94 ± 0.8	7.58	7.52 ± 0.08	30	35 ± 1.1	7.07	0.2	5.0

[a]Data were acquired with the human 5-HT$_{2C}$ INI receptor isoform measuring Gq calcium flux (FLIPR) and β-arrestin-2 recruitment (Tango). pEC$_{50}$ and E_{max} values are shown as the mean ± SEM (n = 3) performed in triplicate, and assays were conducted in parallel with the same drug dilutions. Bias factors toward Gq or β-arrestin-2 were calculated using change in respective relative activity, log(E_{max}/EC$_{50}$), as described previously.[17]



Figure 2. Parallel 5-HT$_{2C}$ screening for functional selectivity of 5-HT$_{2C}$-selective compounds examining Gq-mediated calcium flux (FLIPR, red) and β-arrestin-2 recruitment (Tango, blue). Data were acquired with the human 5-HT$_{2C}$ INI receptor isoform measuring Gq-calcium flux (FLIPR) or β-arrestin-2 recruitment (Tango) performed in triplicate. Assays were conducted in parallel with the same drug dilutions.

The medium sized ethyl group was introduced to position 2 of the benzofuran backbone to further explore the ligand chemical space at this position. As can be seen from compounds **8a**–**f**, the additional ethyl group slightly decreases the 5-HT$_{2C}$ potency of these compounds compared to compounds **7a**–**i** but provides much better selectivity against the 5-HT$_{2B}$ and 5-HT$_{2A}$ receptors. Among them, compound (+)-**8d** showed an EC$_{50}$ value of 11 nM at 5-HT$_{2C}$ receptors, 50-fold selectivity against 5-HT$_{2B}$ (EC$_{50}$ = 550 nM and over 200-fold selectivity against 5-HT$_{2A}$ (EC$_{50}$ = 2210 nM). Given that log(E_{max}/EC$_{50}$) values of (+)-**8d** at both the 5-HT$_{2B}$ and 5-HT$_{2A}$ receptors are much lower (5.69 and 5.30, respectively), we would consider this ligand to be more selective than lorcaserin (5-HT$_{2B}$ log(E_{max}/EC$_{50}$) = 6.27; 5-HT$_{2A}$ log(E_{max}/



Figure 3. Functionally selective (+)-**7e** produces less 5-HT$_{2C}$ G$_q$-mediated desensitization compared to 5-HT as measured by calcium flux (a, b) and by IP accumulation (c–f). 5-HT$_{2C}$ G$_q$-mediated calcium flux comparing desensitization with different pretreatment concentrations of either 5-HT (a) or (+)-**7e** (b) on subsequent stimulated calcium release. Time course for 5-HT$_{2C}$ IP accumulation comparing 1 μM 5-HT or (+)-**7e** at early time points (5–300 min) (c) and at later time points (300–2400 min) (d). Effect of IP accumulation over time on dose–response curves of 5-HT (e) and (+)-**7e** (f).

EC$_{50}$) = 6.44). Compound (+)-**8e** (EC$_{50}$ = 23 nM) is 2-fold weaker than (+)-**8d** at 5-HT$_{2C}$ but shows similar weak 5-HT$_{2B}$ activity (EC$_{50}$ = 433 nM, E_{max} = 19%) and no 5-HT$_{2A}$ activation. Compounds (+)-**8c** and (+)-**8f** are weaker in terms of their activation of 5-HT$_{2C}$ receptors (EC$_{50}$ = 81 and 138 nM, respectively), but both of them show excellent selectivity against the other two receptors as no agonist activity was observed for either 5-HT$_{2B}$ or 5-HT$_{2A}$.

Taken together, the majority of the compounds bearing the new scaffolds **6**–**8** are selective 5-HT$_{2C}$ agonists showing moderate to high selectivity against both the 5-HT$_{2A}$ and 5-HT$_{2B}$ receptors. Given the fact that the E_{max} ranges of most of these compounds at 5-HT$_{2A}$ and 5-HT$_{2B}$ receptors are much lower than those at 5-HT$_{2C}$ receptors, a number of compounds such as (+)-**6d**, (+)-**7c**, (+)-**8d**, and (+)-**8e** represent good candidates for further studies. It is important to note that some of these compounds bind to the 5-HT$_{2A}$ and 5-HT$_{2B}$ receptors at moderate to weak affinities (see Supporting Information, Table S1), but their low intrinsic efficacy excludes them from mediating side effects through activation of those receptors. Although these compounds possess close structural similarity with the melatonin agonist tasimelteon, no activity at the melatonin receptors was anticipated, as the melatonin receptor agonists bear an amide functional group rather than a primary amine.[31] We did in fact test some of these compounds at melatonin MT$_1$ and MT$_2$ receptors examining G$_{i/o}$ function and observed either no activity or very weak agonist activity (EC$_{50}$ > 1 μM) at both receptors (see Supporting Information, Figures S1 and S2).

5-HT$_{2C}$ Functional Selectivity. Agomelatine has been investigated for its antidepressant potential and shown to be a neutral antagonist blocking both G$_q$ activity and β-arrestin

recruitment at 5-HT_{2C} receptors.[8] Despite this study, few 5-HT_{2C} ligands have been thoroughly and systematically investigated for β-arrestin recruitment and ligand bias. Therefore, we sought to investigate β-arrestin recruitment efficacy with the above 5-HT_{2C}-selective benzofuran ligands and to compare their functional selectivity profile to lorcaserin and 5-HT. We measured β-arrestin recruitment activity using a modified reporter assay[32] and compared activities to G_q-mediated calcium flux for our newly synthesized 5-HT_{2C}-selective benzofuran ligands, which was performed in parallel using the same drug dilutions and conditions. Our results indicate that lorcaserin recruited β-arrestin with almost full efficacy compared to 5-HT (Table 2, Figure 2). By contrast, all tested benzofuran compounds exhibited diminished β-arrestin recruitment efficacy (range 22−49%) compared to lorcaserin (89%) and 5-HT (100%), indicating that the 5-HT_{2C}-selective benzofuran ligands exhibit functional selectivity with preference for Gq-mediated calcium flux (Figure 2). To quantify the extent of preference for Gq signaling, we calculated bias factors[17] using relative activities (log E_{max}/EC_{50}) for each respective pathway. The relative activity (log E_{max}/EC_{50}) of compounds can be used as a surrogate for the Black and Leff operational model estimation of log(τ/K_A) provided that the Hill slope does not substantially deviate from 1,[33] which in the case of these compounds it did not. Using lorcaserin as the reference ligand to distinguish our newly synthesized 5-HT_{2C}-selective benzofuran ligands from it, we found that compound (+)-**7e** showed the best preference for Gq signaling (bias factor = 3.8, Table 2). This Gq preference of (+)-**7e** is mainly driven by its extremely weak arrestin recruitment efficacy (E_{max} = 28%), thus demonstrating functionally selective effects compared to lorcaserin and 5-HT.

5-HT_{2C} Desensitization. Considering that arrestin recruitment is reported to cause desensitization at numerous GPCRs[22] and that compound (+)-**7e** exhibited weak arrestin recruitment efficacy, we sought to examine the 5-HT_{2C} desensitization properties comparing full arrestin agonist 5-HT to weak partial arrestin agonist (+)-**7e**. To measure Gq-mediated 5-HT_{2C} desensitization, we first pretreated 5-HT_{2C}-expressing HEK cells with increasing concentrations of either 5-HT or (+)-**7e** for 30 min and then challenged cells after washout to release calcium upon further drug stimulation. Pretreatment with 5-HT concentrations as low as 32 nM depressed the absolute E_{max} without affecting 5-HT's potency, and a 10 μM 5-HT pretreatment concentration completely abolished any additional 5-HT-stimulated calcium flux (Figure 3a). By contrast, (+)-**7e** did not show E_{max} depression at pretreatment concentrations below 1 μM (Figure 3b), suggesting that (+)-**7e** was not as efficient to desensitize 5-HT_{2C} Gq-mediated calcium flux compared to similar 5-HT concentrations.

Although calcium flux is commonly investigated as a functional readout of G_q-coupled receptor desensitization, calcium flux does not allow full receptor occupancy given its short time duration. In addition, calcium flux is downstream from PLC-mediated phosphoinositide (PI) hydrolysis, which has been investigated as functional readout of 5-HT_{2C} desensitization by measuring ^{3}H-inositol phosphates (IP) accumulation over time.[34] Therefore, we compared full arrestin agonist 5-HT to partial arrestin agonist (+)-**7e**, expecting to observe a loss of IP accumulation over time indicative of 5-HT_{2C} desensitization. First, 5-HT_{2C}-expressing cells produced expected elevated basal levels of ^{3}H-inositol phosphates (Figure 3e,f), consistent with a high level of constitutive activity at this receptor isoform.[35,36] Despite the elevated level of ^{3}H-phosphoinositides, both 5-HT and (+)-**7e** at maximum receptor occupancy (1 μM, Figure S3 in Supporting Information) produced a rapid and robust increase in ^{3}H-phosphoinositides after only 5 min of drug incubation peaking around 60 min (Figure 3c). In fact, IP accumulation for both 5-HT and (+)-**7e** was sustained up to 5 h (300 min) with no depression in absolute E_{max} (Figure 3e,f). 5-HT incubation at longer time points, however, showed decreasing IP accumulation at 600 min (10 h) with a gradual reduction back to basal levels at 40 h (Figure 3d). Although the 5-HT E_{max} was completely abolished by at least 30 h of incubation (Figure 3e), (+)-**7e** produced a sustained IP accumulation and only began to show a significant decrease in E_{max} after 20 h of drug incubation (Figure 3d). Comparison of the desensitization rates of 5-HT and (+)-**7e** revealed that (+)-**7e** at 1 μM produced slower reduction in IP accumulation over time (Figure S4). In fact, (+)-**7e** still retained a dose−response at 30 h (Figure 3f), whereas 5-HT did not. Given that (+)-**7e** was previously found to produce weaker arrestin recruitment compared to 5-HT, these results support the finding that weaker desensitization is a unique contributor to (+)-**7e**'s functional selectivity profile.

■ CONCLUSIONS

Inspired by the cross-talk between serotonergic and melatonergic biological functions and the structural similarity of our previous 2-phenylcyclopropylmethylamine scaffold with the melatonin receptor agonist tasimelteon, we designed and synthesized a series of compounds bearing either a 2,3-dihydrobenzofuran or a benzofuran scaffold. Pharmacological profiling of these new compounds at 5-HT_{2C}, 5-HT_{2B}, and 5-HT_{2A} receptors identified a number of compounds showing high potency and good selectivity as 5-HT_{2C} agonists. Parallel testing of selected compounds in both Gq-mediated calcium flux and β-arrestin recruitment assays revealed that these compounds show functional selectivity with weaker arrestin recruitment and less desensitization properties compared to 5-HT. These findings open the possibility of discovering novel functionally selective compounds for the 5-HT_{2C} receptor, which will serve as tools to identify therapeutically relevant 5-HT_{2C} signaling pathways.

■ EXPERIMENTAL SECTION

General. All chemicals and solvents were purchased from Sigma-Aldrich or Fisher Scientific, and were used as obtained without further purification. Microwave reactions were run in a Biotage Initiator microwave reactor. Synthetic intermediates were purified on 230−400 mesh silica gel using a Teledyne CombiFlash R_f flash chromatography. ^{1}H and ^{13}C NMR spectra were recorded on Bruker DPX-400 or AVANCE-400 spectrometers at 400 and 100 MHz, respectively. NMR chemical shifts were reported in δ (ppm) using residual solvent peaks as standards ($CDCl_3$, 7.26 (H), 77.16 (C); CD_3OD, 3.31 (H), 49.00 (C); DMSO-d_6, 2.50 (H), 39.52 (C)). Mass spectra were measured using an LCMS-IT-TOF (Shimadzu) mass spectrometer in ESI mode. Purity of all final compounds (greater than 95% in all cases) was determined by analytical HPLC (ACE 3AQ C_{18} column (150 mm × 4.6 mm, particle size 3 μm); 0.05% TFA in H_2O/0.05% TFA in MeOH gradient eluting system; flow rate = 1.0 mL/min). Chiral separation of synthetic intermediates was conducted using RegisPack (25 cm × 21.1 mm, 10 μm) or ChromegaChiral CCJ (25 cm × 20 mm, 10 μm) chiral columns, and *n*-hexane/ethanol as the eluent. Optical rotations were recorded on a Rudolph Research Autopol IV automatic polarimeter.

The synthetic procedures, chiral separation methods, and characterization data of all intermediates can be found in Supporting Information. All intermediates subjected to chiral preparative-HPLC separation were prepared with an optical purity of >90% ee (determined with analytical HPLC using a RegisPack (25 cm × 4.6 mm, 10 μm) or ChromegaChiral CCJ (25 cm × 4.6 mm, 10 μm) chiral column and *n*-hexane/ethanol as the eluent). Compounds (−)-**6a**−**f**, (+)-**6a**−**f**, (−)-**7a**−**i**, (+)-**7a**−**i**, (−)-**8a**−**f**, and (+)-**8a**−**f** were all obtained as white solids.

(−)-(2-(5-Methoxy-2,3-dihydrobenzofuran-4-yl)-cyclopropyl)methanamine Trifluoroacetate ((−)-6a). The HCl salt obtained using the general methods as described was further purified using preparative HPLC (Shimadzu HPLC system; ACE 5AQ C18 column (150 mm × 21.2 mm, particle size 5 μm); 0.05% TFA in H_2O/0.05% TFA in MeOH gradient eluting system; flow rate = 17.0 mL/min), and the title compound was obtained as a white solid. ^{1}H NMR (CD_3OD) δ 6.66 (d, *J* = 8.8 Hz, 1H), 6.54 (d, *J* = 8.8 Hz, 1H), 4.53−4.42 (m, 2H), 3.78 (s, 3H), 3.25−3.16 (m, 2H), 3.11 (dd, *J* = 12.8, 6.8 Hz, 1H), 2.89 (dd, *J* = 12.8, 8.4 Hz, 1H), 1.78−1.75 (m, 1H), 1.39−1.37 (m, 1H), 1.15−1.09 (m, 4H), 0.98−0.93 (m, 1H); ^{13}C NMR (CD_3OD) δ 162.8 (q, J_{CF} = 34.9 Hz), 155.5, 154.4, 129.6, 126.3, 118.2 (q, J_{CF} = 290.7 Hz), 111.1, 107.9, 72.4, 56.6, 45.6, 30.5, 18.4, 17.8, 12.6. HRMS calcd for $C_{13}H_{18}NO_2^+$ ([M + H]$^+$): 220.1332; found, 220.1333. $[\alpha]_D^{20}$ −39.0 (*c* 0.1, MeOH).

(+)-(2-(5-Methoxy-2,3-dihydrobenzofuran-4-yl)cyclopropyl)-methanamine Trifluoroacetate ((+)-6a). The HCl salt obtained using the general methods as described was further purified using preparative HPLC as described for compound (−)-**6a**, and the title compound was obtained as a white solid. ^{1}H NMR (CD_3OD) δ 6.66 (d, *J* = 8.8 Hz, 1H), 6.54 (d, *J* = 8.8 Hz, 1H), 4.53−4.42 (m, 2H), 3.78 (s, 3H), 3.25−3.16 (m, 2H), 3.11 (dd, *J* = 12.8, 6.8 Hz, 1H), 2.89 (dd, *J* = 12.8, 8.4 Hz, 1H), 1.78−1.75 (m, 1H), 1.39−1.37 (m, 1H), 1.15−1.09 (m, 4H), 0.98−0.93 (m, 1H); ^{13}C NMR (CD_3OD) δ 162.8 (q, J_{CF} = 34.8 Hz), 155.5, 154.4, 129.6, 126.3, 118.2 (q, J_{CF} = 290.7 Hz), 111.1, 107.9, 72.4, 56.6, 45.6, 30.5, 18.4, 17.8, 12.6. HRMS calcd for $C_{13}H_{18}NO_2^+$ ([M + H]$^+$): 220.1332; found, 220.1332. $[\alpha]_D^{20}$ +34.7 (*c* 0.5, MeOH).

(−)-(2-(5-Ethoxy-2,3-dihydrobenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-6b). ^{1}H NMR (CD_3OD) δ 6.65 (d, *J* = 8.4 Hz, 1H), 6.51 (d, *J* = 8.4 Hz, 1H), 4.59−4.44 (m, 2H), 4.02−3.95 (m, 2H), 3.25−3.18 (m, 2H), 3.14 (dd, *J* = 13.2, 6.8 Hz, 1H), 2.89 (dd, *J* = 13.2, 8.0 Hz, 1H), 1.81−1.77 (m, 1H), 1.51−1.46 (m, 1H), 1.41 (t, *J* = 6.8 Hz, 3H), 1.21−1.16 (m, 1H), 0.99−0.94 (m, 1H). HRMS calcd for $C_{14}H_{20}NO_2^+$ ([M + H]$^+$): 234.1489; found, 234.1486. $[\alpha]_D^{20}$ −42.0 (*c* 0.1, MeOH).

(+)-(2-(5-Ethoxy-2,3-dihydrobenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-6b). ^{1}H NMR (CD_3OD) δ 6.65 (d, *J* = 8.4 Hz, 1H), 6.51 (d, *J* = 8.4 Hz, 1H), 4.59−4.44 (m, 2H), 4.01−3.95 (m, 2H), 3.25−3.18 (m, 2H), 3.14 (dd, *J* = 13.2, 6.8 Hz, 1H), 2.89 (dd, *J* = 13.2, 8.0 Hz, 1H), 1.80−1.77 (m, 1H), 1.51−1.48 (m, 1H), 1.41 (t, *J* = 7.2 Hz, 3H), 1.21−1.17 (m, 1H), 0.99−0.94 (m, 1H); ^{13}C NMR (CD_3OD) δ 155.4, 153.6, 129.4, 126.6, 112.6, 107.9, 72.4, 65.8, 45.6, 30.6, 18.4, 18.2, 15.5, 12.8. HRMS calcd for $C_{14}H_{20}NO_2^+$ ([M + H]$^+$): 234.1489; found, 234.1482. $[\alpha]_D^{20}$ +37.0 (*c* 0.1, MeOH).

(−)-(2-(5-Propoxy-2,3-dihydrobenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-6c). ^{1}H NMR (CD_3OD) δ 6.64 (d, *J* = 8.4 Hz, 1H), 6.51 (d, *J* = 8.4 Hz, 1H), 4.51−4.45 (m, 2H), 3.91−3.83 (m, 2H), 3.25−3.20 (m, 3H), 2.81 (dd, *J* = 13.2, 8.8 Hz, 1H), 1.86−1.77 (m, 3H), 1.55−1.52 (m, 1H), 1.23−1.20 (m, 1H), 1.07 (t, *J* = 7.2 Hz, 3H), 0.99−0.94 (m, 1H). HRMS calcd for $C_{15}H_{22}NO_2^+$ ([M + H]$^+$): 248.1645; found, 248.1648. $[\alpha]_D^{20}$ −47.2 (*c* 0.1, MeOH).

(+)-(2-(5-Propoxy-2,3-dihydrobenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-6c). ^{1}H NMR (CD_3OD) δ 6.64 (d, *J* = 8.4 Hz, 1H), 6.51 (d, *J* = 8.4 Hz, 1H), 4.53−4.45 (m, 2H), 3.91−3.83 (m, 2H), 3.25−3.20 (m, 3H), 2.81 (dd, *J* = 13.2, 8.8 Hz, 1H), 1.86−1.77 (m, 3H), 1.57−1.52 (m, 1H), 1.23−1.19 (m, 1H), 1.07 (t, *J* = 7.2 Hz, 3H), 0.99−0.94 (m, 1H); ^{13}C NMR (CD_3OD) δ 155.4, 153.7, 129.4, 126.7, 112.5, 107.9, 72.3, 71.9, 45.6, 30.6, 24.0, 18.4, 18.2, 12.9, 11.2. HRMS calcd for $C_{15}H_{22}NO_2^+$ ([M + H]$^+$): 248.1645; found, 248.1638. $[\alpha]_D^{20}$ +44.7 (*c* 0.15, MeOH).

(−)-(2-(5-(Allyloxy)-2,3-dihydrobenzofuran-4-yl)-cyclopropyl)methanamine Hydrochloride ((−)-6d). ^{1}H NMR (CD_3OD) δ 6.67 (d, *J* = 8.4 Hz, 1H), 6.51 (d, *J* = 8.4 Hz, 1H), 6.15−6.08 (m, 1H), 5.42 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.28 (dd, *J* = 10.4, 1.2 Hz, 1H), 4.53−4.45 (m, 4H), 3.27−3.19 (m, 2H), 3.11 (dd, *J* = 12.8, 7.2 Hz, 1H), 2.92 (dd, *J* = 12.8, 8.0 Hz, 1H), 1.83−1.80 (m, 1H), 1.49−1.47 (m, 1H), 1.22−1.16 (m, 1H), 1.00−0.95 (m, 1H). HRMS calcd for $C_{15}H_{20}NO_2^+$ ([M + H]$^+$): 246.1489; found, 246.1483. $[\alpha]_D^{20}$ −62.7 (*c* 0.1, MeOH).

(+)-(2-(5-(Allyloxy)-2,3-dihydrobenzofuran-4-yl)-cyclopropyl)methanamine Hydrochloride ((−)-6d). ^{1}H NMR (CD_3OD) δ 6.67 (d, *J* = 8.4 Hz, 1H), 6.51 (d, *J* = 8.4 Hz, 1H), 6.15−6.08 (m, 1H), 5.42 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.28 (dd, *J* = 10.4, 1.2 Hz, 1H), 4.51−4.45 (m, 4H), 3.26−3.19 (m, 2H), 3.11 (dd, *J* = 12.8, 7.2 Hz, 1H), 2.92 (dd, *J* = 12.8, 8.0 Hz, 1H), 1.83−1.80 (m, 1H), 1.49−1.47 (m, 1H), 1.22−1.16 (m, 1H), 1.00−0.95 (m, 1H); ^{13}C NMR (CD_3OD) δ 155.7, 153.3, 135.5, 129.5, 126.9, 118.2, 113.1, 107.9, 72.4, 71.4, 45.6, 30.6, 18.4, 18.2, 12.8. HRMS calcd for $C_{15}H_{20}NO_2^+$ ([M + H]$^+$): 246.1489; found, 246.1485. $[\alpha]_D^{20}$ +56.3 (*c* 0.15, MeOH).

(−)-(2-(5-(Cyclopropylmethoxy)-2,3-dihydrobenzofuran-4-yl)cyclopropyl)methanamine Hydrochloride ((−)-6e). ^{1}H NMR (CD_3OD) δ 6.63 (d, *J* = 8.8 Hz, 1H), 6.51 (d, *J* = 8.4 Hz, 1H), 4.53−4.44 (m, 2H), 3.77 (d, *J* = 6.8 Hz, 2H), 3.24−3.18 (m, 2H), 3.13 (dd, *J* = 12.8, 7.2 Hz, 1H), 2.98 (dd, *J* = 12.8, 8.0 Hz, 1H), 1.83−1.80 (m, 1H), 1.48−1.45 (m, 1H), 1.30−1.22 (m, 2H), 1.01−0.98 (m, 1H), 0.65−0.62 (m, 2H), 0.39−0.37 (m, 2H). HRMS calcd for $C_{16}H_{22}NO_2^+$ ([M + H]$^+$): 260.1645; found, 260.1641. $[\alpha]_D^{20}$ −46.7 (*c* 0.05, MeOH).

(+)-(2-(5-(Cyclopropylmethoxy)-2,3-dihydrobenzofuran-4-yl)cyclopropyl)methanamine Hydrochloride ((+)-6e). ^{1}H NMR (CD_3OD) δ 6.62 (d, *J* = 8.8 Hz, 1H), 6.50 (d, *J* = 8.4 Hz, 1H), 4.53−4.42 (m, 2H), 3.77 (d, *J* = 7.2 Hz, 2H), 3.24−3.18 (m, 2H), 3.13 (dd, *J* = 12.8, 7.2 Hz, 1H), 2.99 (dd, *J* = 12.8, 8.0 Hz, 1H), 1.83−1.80 (m, 1H), 1.48−1.45 (m, 1H), 1.30−1.22 (m, 2H), 1.01−0.98 (m, 1H), 0.65−0.62 (m, 2H), 0.40−0.37 (m, 2H); ^{13}C NMR (CD_3OD) δ 155.5, 153.8, 129.4, 126.7, 112.7, 107.9, 75.3, 72.4, 45.7, 30.6, 18.6, 18.2, 12.7, 11.5, 4.0, 3.7. HRMS calcd for $C_{16}H_{22}NO_2^+$ ([M + H]$^+$): 260.1645; found, 260.1635. $[\alpha]_D^{20}$ +34.7 (*c* 0.2, MeOH).

(−)-(2-(5-(2-Fluoroethoxy)-2,3-dihydrobenzofuran-4-yl)-cyclopropyl)methanamine Hydrochloride ((−)-6f). ^{1}H NMR (CD_3OD) δ 6.69 (d, *J* = 8.4 Hz, 1H), 6.54 (d, *J* = 8.4 Hz, 1H), 4.84−4.82 (m, 1H), 4.73−4.71 (m, 1H), 4.53−4.45 (m, 2H), 4.23−4.12 (m, 2H), 3.25−3.15 (m, 2H), 3.13 (dd, *J* = 13.2, 7.2 Hz, 1H), 2.93 (dd, *J* = 12.8, 8.0 Hz, 1H), 1.82−1.78 (m, 1H), 1.47−1.44 (m, 1H), 1.22−1.19 (m, 1H), 1.00−0.95 (m, 1H); ^{13}C NMR (CD_3OD) δ 155.9, 153.2, 129.7, 127.0, 112.8, 108.0, 83.8 (d, J_{CF} = 166.5 Hz), 72.5, 69.8 (d, J_{CF} = 18.8 Hz), 45.5, 30.6, 18.6, 18.0, 12.6. HRMS calcd for $C_{14}H_{19}FNO_2^+$ ([M + H]$^+$): 252.1394; found, 252.1388. $[\alpha]_D^{20}$ −56.0 (*c* 0.1, MeOH).

(+)-(2-(5-(2-Fluoroethoxy)-2,3-dihydrobenzofuran-4-yl)-cyclopropyl)methanamine Hydrochloride ((+)-6f). ^{1}H NMR (CD_3OD) δ 6.69 (d, *J* = 8.4 Hz, 1H), 6.54 (d, *J* = 8.8 Hz, 1H), 4.84−4.82 (m, 1H), 4.73−4.70 (m, 1H), 4.53−4.45 (m, 2H), 4.23−4.12 (m, 2H), 3.26−3.19 (m, 2H), 3.13 (dd, *J* = 13.2, 7.2 Hz, 1H), 2.93 (dd, *J* = 12.8, 8.0 Hz, 1H), 1.83−1.79 (m, 1H), 1.47−1.45 (m, 1H), 1.23−1.18 (m, 1H), 1.00−0.95 (m, 1H); ^{13}C NMR (CD_3OD) δ 156.0, 153.2, 129.7, 127.1, 112.9, 108.0, 83.8 (d, J_{CF} = 166.3 Hz), 72.5, 69.8 (d, J_{CF} = 18.7 Hz), 45.5, 30.6, 18.6, 18.0, 12.6. HRMS calcd for $C_{14}H_{19}FNO_2^+$ ([M + H]$^+$): 252.1394; found, 252.1397. $[\alpha]_D^{20}$ +68.0 (*c* 0.1, MeOH).

(−)-(2-(5-Methoxybenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-7a). ^{1}H NMR (CD_3OD) δ 7.71 (d, *J* = 2.4 Hz, 1H), 7.33 (d, *J* = 9.2 Hz, 1H), 6.99 (d, *J* = 8.8 Hz, 1H), 6.91 (d, *J* = 2.4 Hz, 1H), 3.91 (s, 3H), 3.17 (dd, *J* = 12.8, 6.8 Hz, 1H), 2.97 (dd, *J* = 12.8, 8.4 Hz, 1H), 2.07−2.02 (m, 1H), 1.46−1.41 (m, 1H), 1.28−1.23 (m, 1H), 1.14−1.09 (m, 1H); ^{13}C NMR (CD_3OD) δ 155.8, 151.6, 147.4, 129.5, 121.0, 110.7, 109.8, 106.4, 57.0, 45.6, 18.6,

17.2, 12.9. HRMS calcd for $C_{13}H_{16}NO_2^+$ ([M + H]$^+$): 218.1176; found, 252.1181. $[\alpha]_D^{20}$ −56.0 (*c* 0.2, MeOH).

(+)-(2-(5-Methoxybenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-7a). ^{1}H NMR (CD_3OD) δ 7.71 (d, *J* = 2.0 Hz, 1H), 7.33 (d, *J* = 8.8 Hz, 1H), 6.99 (d, *J* = 9.2 Hz, 1H), 6.91 (d, *J* = 1.6 Hz, 1H), 3.91 (s, 3H), 3.17 (dd, *J* = 13.2, 6.8 Hz, 1H), 2.98 (dd, *J* = 12.8, 8.0 Hz, 1H), 2.08−2.03 (m, 1H), 1.47−1.43 (m, 1H), 1.29−1.24 (m, 1H), 1.15−1.10 (m, 1H); ^{13}C NMR (CD_3OD) δ 155.8, 151.6, 147.4, 129.5, 121.0, 110.7, 109.9, 106.3, 57.1, 45.6, 18.6, 17.3, 13.0. HRMS calcd for $C_{13}H_{16}NO_2^+$ ([M + H]$^+$): 218.1176; found, 252.1165. $[\alpha]_D^{20}$ +60.3 (*c* 0.3, MeOH).

(−)-(2-(5-Ethoxybenzofuran-4-yl)cyclopropyl)methanamine Hydrochloride ((−)-7b). ^{1}H NMR (CD_3OD) δ 7.70 (d, *J* = 2.0 Hz, 1H), 7.29 (d, *J* = 8.8 Hz, 1H), 6.95 (d, *J* = 8.8 Hz, 1H), 6.90 (d, *J* = 2.0 Hz, 1H), 4.15−4.07 (m, 2H), 3.22 (dd, *J* = 13.2, 6.8 Hz, 1H), 2.96 (dd, *J* = 13.2, 8.0 Hz, 1H), 2.11−2.05 (m, 1H), 1.58−1.54 (m, 1H), 1.46 (t, *J* = 7.2 Hz, 3H), 1.32−1.28 (m, 1H), 1.14−1.09 (m, 1H); ^{13}C NMR (CD_3OD) δ 155.0, 151.6, 147.2, 129.3, 121.5, 111.4, 110.5, 106.4, 66.3, 45.6, 18.6, 17.6, 15.6, 13.2. HRMS calcd for $C_{14}H_{18}NO_2^+$ ([M + H]$^+$): 232.1332; found, 232.1329. $[\alpha]_D^{20}$ −53.4 (*c* 0.5, MeOH).

(+)-(2-(5-Ethoxybenzofuran-4-yl)cyclopropyl)methanamine Hydrochloride ((+)-7b). ^{1}H NMR (CD_3OD) δ 7.70 (d, *J* = 2.4 Hz, 1H), 7.29 (d, *J* = 8.8 Hz, 1H), 6.96 (d, *J* = 9.2 Hz, 1H), 6.90 (d, *J* = 2.4 Hz, 1H), 4.15−4.08 (m, 2H), 3.22 (dd, *J* = 13.2, 6.8 Hz, 1H), 2.96 (dd, *J* = 13.2, 8.0 Hz, 1H), 2.10−2.07 (m, 1H), 1.57−1.55 (m, 1H), 1.46 (t, *J* = 7.2 Hz, 3H), 1.33−1.28 (m, 1H), 1.14−1.10 (m, 1H); ^{13}C NMR (CD_3OD) δ 155.0, 151.6, 147.3, 129.3, 121.5, 111.4, 110.6, 106.4, 66.3, 45.6, 18.6, 17.6, 15.6, 13.2. HRMS calcd for $C_{14}H_{18}NO_2^+$ ([M + H]$^+$): 232.1332; found, 232.1332. $[\alpha]_D^{20}$ +50.7 (*c* 0.3, MeOH).

(−)-(2-(5-Propoxybenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-7c). ^{1}H NMR (CD_3OD) δ 7.71 (d, *J* = 2.0 Hz, 1H), 7.29 (d, *J* = 8.8 Hz, 1H), 6.96 (d, *J* = 8.8 Hz, 1H), 6.91 (d, *J* = 1.6 Hz, 1H), 4.04−3.97 (m, 2H), 3.32 (dd, *J* = 13.2, 6.8 Hz, 1H), 2.88 (dd, *J* = 13.2, 8.8 Hz, 1H), 2.14−2.08 (m, 1H), 1.91−1.85 (m, 2H), 1.62−1.59 (m, 1H), 1.35−1.29 (m, 1H), 1.14−1.09 (m, 4H); ^{13}C NMR (CD_3OD) δ 155.1, 151.6, 147.3, 129.2, 121.5, 111.4, 110.5, 106.4, 72.5, 45.5, 24.2, 18.5, 17.8, 13.3, 11.2. HRMS calcd for $C_{15}H_{20}NO_2^+$ ([M + H]$^+$): 246.1489; found, 246.1484. $[\alpha]_D^{20}$ −53.7 (*c* 0.3, MeOH).

(+)-(2-(5-Propoxybenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-7c). ^{1}H NMR (CD_3OD) δ 7.71 (d, *J* = 2.0 Hz, 1H), 7.30 (d, *J* = 8.8 Hz, 1H), 6.97 (d, *J* = 8.8 Hz, 1H), 6.91 (d, *J* = 1.2 Hz, 1H), 4.05−3.98 (m, 2H), 3.32 (dd, *J* = 12.8, 6.4 Hz, 1H), 2.88 (dd, *J* = 12.8, 8.8 Hz, 1H), 2.14−2.09 (m, 1H), 1.91−1.85 (m, 2H), 1.64−1.60 (m, 1H), 1.35−1.30 (m, 1H), 1.15−1.09 (m, 4H); ^{13}C NMR (CD_3OD) δ 155.1, 151.6, 147.2, 129.2, 121.5, 111.5, 110.5, 106.4, 72.5, 45.6, 24.2, 18.6, 17.8, 13.3, 11.2. HRMS calcd for $C_{15}H_{20}NO_2^+$ ([M + H]$^+$): 246.1489; found, 246.1494. $[\alpha]_D^{20}$ +50.5 (*c* 0.2, MeOH).

(−)-(2-(5-(Allyloxy)benzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-7d). ^{1}H NMR (CD_3OD) δ 7.72 (d, *J* = 2.0 Hz, 1H), 7.31 (d, *J* = 9.2 Hz, 1H), 6.99 (d, *J* = 8.8 Hz, 1H), 6.92 (d, *J* = 2.0 Hz, 1H), 6.23−6.12 (m, 1H), 5.47 (dd, *J* = 17.6, 1.6 Hz, 1H), 5.32 (d, *J* = 9.6 Hz, 1H), 4.63 (d, *J* = 5.2 Hz, 2H), 3.20 (dd, *J* = 12.8, 7.2 Hz, 1H), 2.98 (dd, *J* = 12.8, 8.0 Hz, 1H), 2.14−2.08 (m, 1H), 1.57−1.52 (m, 1H), 1.34−1.29 (m, 1H), 1.15−1.10 (m, 1H); ^{13}C NMR (CD_3OD) δ 154.8, 151.7, 147.4, 135.5, 129.3, 121.7, 118.3, 111.8, 110.6, 106.4, 71.8, 45.5, 18.7, 17.6, 13.1. HRMS calcd for $C_{15}H_{18}NO_2^+$ ([M + H]$^+$): 244.1332; found, 244.1328. $[\alpha]_D^{20}$ −52.5 (*c* 0.2, MeOH).

(+)-(2-(5-(Allyloxy)benzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-7d). ^{1}H NMR (CD_3OD) δ 7.72 (d, *J* = 2.4 Hz, 1H), 7.31 (d, *J* = 9.2 Hz, 1H), 6.99 (d, *J* = 8.8 Hz, 1H), 6.92 (d, *J* = 2.4 Hz, 1H), 6.22−6.14 (m, 1H), 5.48 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.32 (dd, *J* = 10.4, 1.2 Hz, 1H), 4.64 (d, *J* = 5.6 Hz, 2H), 3.21 (dd, *J* = 12.8, 6.8 Hz, 1H), 2.98 (dd, *J* = 13.2, 8.0 Hz, 1H), 2.15−2.09 (m, 1H), 1.58−1.54 (m, 1H), 1.35−1.30 (m, 1H), 1.16−1.11 (m, 1H); ^{13}C NMR (CD_3OD) δ 154.8, 151.8, 147.4, 135.5, 129.3, 121.8, 118.3, 111.9, 110.6, 106.4, 71.9, 45.6, 18.7, 17.6, 13.2. HRMS calcd for $C_{15}H_{18}NO_2^+$ ([M + H]$^+$): 244.1332; found, 244.1324. $[\alpha]_D^{20}$ +57.0 (*c* 0.2, MeOH).

(−)-(2-(5-(2-Fluoroethoxy)benzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-7e). ^{1}H NMR (CD_3OD) δ 7.72 (d, *J* = 2.4 Hz, 1H), 7.33 (d, *J* = 8.8 Hz, 1H), 6.99 (d, *J* = 8.8 Hz, 1H), 6.92 (d, *J* = 2.0 Hz, 1H), 4.90−4.88 (m, 1H), 4.78−4.75 (m, 1H), 4.36−4.26 (m, 2H), 3.21 (dd, *J* = 13.2, 7.2 Hz, 1H), 2.98 (dd, *J* = 13.2, 8.0 Hz, 1H), 2.12−2.09 (m, 1H), 1.53−1.50 (m, 1H), 1.35−1.30 (m, 1H), 1.15−1.11 (m, 1H); ^{13}C NMR (CD_3OD) δ 154.7, 151.9, 147.5, 129.5, 122.1, 111.7, 110.8, 106.5, 83.9 (d, J_{CF} = 166.5 Hz), 70.4 (d, J_{CF} = 18.7 Hz), 45.5, 18.8, 17.5, 13.0. HRMS calcd for $C_{14}H_{17}FNO_2^+$ ([M + H]$^+$): 250.1238; found, 250.1231. $[\alpha]_D^{20}$ −93.0 (*c* 0.2, MeOH).

(+)-(2-(5-(2-Fluoroethoxy)benzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-7e). ^{1}H NMR (CD_3OD) δ 7.72 (d, *J* = 2.0 Hz, 1H), 7.33 (d, *J* = 8.8 Hz, 1H), 6.99 (d, *J* = 8.8 Hz, 1H), 6.93 (d, *J* = 2.0 Hz, 1H), 4.90−4.88 (m, 1H), 4.77−4.75 (m, 1H), 4.36−4.25 (m, 2H), 3.20 (dd, *J* = 12.8, 7.2 Hz, 1H), 2.98 (dd, *J* = 12.8, 8.0 Hz, 1H), 2.13−2.08 (m, 1H), 1.53−1.49 (m, 1H), 1.35−1.30 (m, 1H), 1.15−1.10 (m, 1H). HRMS calcd for $C_{14}H_{17}FNO_2^+$ ([M + H]$^+$): 250.1238; found, 250.1231. $[\alpha]_D^{20}$ +88.9 (*c* 0.1, MeOH).

(−)-(2-(5-(Cyclopropylmethoxy)benzofuran-4-yl)-cyclopropyl)methanamine Hydrochloride ((−)-7f). ^{1}H NMR (CD_3OD) δ 7.70 (d, *J* = 2.0 Hz, 1H), 7.29 (d, *J* = 8.8 Hz, 1H), 6.94 (d, *J* = 8.8 Hz, 1H), 6.91 (d, *J* = 2.0 Hz, 1H), 3.90 (d, J = 7.2 Hz, 2H), 3.21 (dd, *J* = 12.8, 7.2 Hz, 1H), 3.03 (dd, *J* = 12.8, 8.0 Hz, 1H), 2.12−2.09 (m, 1H), 1.54−1.51 (m, 1H), 1.37−1.32 (m, 2H), 1.17−1.13 (m, 1H), 0.68−0.63 (m, 2H), 0.44−0.40 (m, 2H); ^{13}C NMR (CD_3OD) δ 155.2, 151.6, 147.3, 129.2, 121.6, 111.7, 110.6, 106.4, 75.9, 45.6, 18.8, 17.6, 13.1, 11.6, 4.0, 3.7. HRMS calcd for $C_{16}H_{20}NO_2^+$ ([M + H]$^+$): 258.1489; found, 258.1501. $[\alpha]_D^{20}$ −76.0 (*c* 0.2, MeOH).

(+)-(2-(5-(Cyclopropylmethoxy)benzofuran-4-yl)-cyclopropyl)methanamine Hydrochloride ((+)-7f). ^{1}H NMR (CD_3OD) δ 7.70 (d, *J* = 2.0 Hz, 1H), 7.29 (d, *J* = 8.8 Hz, 1H), 6.94 (d, *J* = 8.8 Hz, 1H), 6.91 (d, *J* = 2.0 Hz, 1H), 3.90 (d, J = 6.8 Hz, 2H), 3.21 (dd, *J* = 12.8, 7.2 Hz, 1H), 3.03 (dd, *J* = 12.8, 8.0 Hz, 1H), 2.13−2.08 (m, 1H), 1.54−1.51 (m, 1H), 1.38−1.32 (m, 2H), 1.16−1.11 (m, 1H), 0.68−0.63 (m, 2H), 0.43−0.39 (m, 2H). HRMS calcd for $C_{16}H_{20}NO_2^+$ ([M + H]$^+$): 258.1489; found, 258.1477. $[\alpha]_D^{20}$ +73.3 (*c* 0.3, MeOH).

(−)-(2-(5-Isopropoxybenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-7g). ^{1}H NMR (CD_3OD) δ 7.70 (d, *J* = 2.0 Hz, 1H), 7.28 (d, *J* = 8.8 Hz, 1H), 6.97 (d, *J* = 8.8 Hz, 1H), 6.88 (d, *J* = 2.0 Hz, 1H), 4.65−4.57 (m, 1H), 3.37 (dd, *J* = 12.8, 6.0 Hz, 1H), 2.83 (dd, *J* = 12.8, 8.8 Hz, 1H), 2.14−2.08 (m, 1H), 1.62−1.56 (m, 1H), 1.38 (d, *J* = 6.0 Hz, 3H), 1.34 (d, *J* = 6.0 Hz, 3H), 1.32−1.29 (m, 1H), 1.13−1.08 (m, 1H); ^{13}C NMR (CD_3OD) δ 153.6, 151.7, 147.2, 129.0, 123.1, 114.0, 110.6, 106.4, 73.3, 45.6, 22.9, 22.7, 18.7, 18.0, 13.3. HRMS calcd for $C_{15}H_{20}NO_2^+$ ([M + H]$^+$): 246.1489; found, 246.1486. $[\alpha]_D^{20}$ −48.5 (*c* 0.2, MeOH).

(+)-(2-(5-Isopropoxybenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-7g). ^{1}H NMR (CD_3OD) δ 7.70 (d, *J* = 2.4 Hz, 1H), 7.29 (d, *J* = 8.8 Hz, 1H), 6.97 (d, *J* = 8.8 Hz, 1H), 6.87 (d, *J* = 1.2 Hz, 1H), 4.65−4.57 (m, 1H), 3.36 (dd, *J* = 13.2, 6.0 Hz, 1H), 2.83 (dd, *J* = 12.8, 8.8 Hz, 1H), 2.14−2.08 (m, 1H), 1.62−1.56 (m, 1H), 1.38 (d, *J* = 6.0 Hz, 3H), 1.34 (d, *J* = 6.0 Hz, 3H), 1.32−1.29 (m, 1H), 1.12−1.07 (m, 1H). HRMS calcd for $C_{15}H_{20}NO_2^+$ ([M + H]$^+$): 246.1489; found, 246.1487. $[\alpha]_D^{20}$ +46.0 (*c* 0.2, MeOH).

(−)-(2-(5-((2-Fluoroallyl)oxy)benzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-7h). ^{1}H NMR (DMSO-d_6) δ 8.00 (br, 3H), 7.95 (d, *J* = 2.0 Hz, 1H), 7.39 (d, *J* = 8.8 Hz, 1H), 7.04 (d, *J* = 8.8 Hz, 1H), 7.00 (d, *J* = 2.0 Hz, 1H), 4.94 (dd, *J* = 8.8, 3.2 Hz, 1H), 4.86 (dd, *J* = 25.2, 2.8 Hz, 1H), 4.68 (d, *J* = 14.8 Hz, 2H), 3.16−3.14 (m, 1H), 2.76−2.71 (m, 1H), 2.13−2.08 (m, 1H), 1.65−1.59 (m, 1H), 1.17−1.13 (m, 1H), 1.09−1.05 (m, 1H); ^{13}C NMR (CD_3OD) δ 163.4 (d, J_{CF} = 256.4 Hz), 154.3, 152.1, 147.5, 129.4, 122.6, 112.4, 110.8, 106.5, 94.8 (d, J_{CF} = 16.9 Hz), 68.8 (d, J_{CF} = 31.7 Hz), 45.4, 18.7, 17.5, 13.2. HRMS calcd for $C_{15}H_{17}FNO_2^+$ ([M + H]$^+$): 262.1238; found, 262.1234. $[\alpha]_D^{20}$ −67.0 (*c* 0.2, MeOH).

(+)-(2-(5-((2-Fluoroallyl)oxy)benzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-7h). ^{1}H NMR (DMSO-d_6) δ 8.09 (br, 3H), 7.95 (d, *J* = 2.0 Hz, 1H), 7.38 (d, *J* = 8.8 Hz, 1H), 7.04

(d, J = 8.8 Hz, 1H), 7.01 (d, J = 2.0 Hz, 1H), 4.93 (dd, J = 10.2, 3.2 Hz, 1H), 4.85 (dd, J = 23.2, 3.2 Hz, 1H), 4.68 (d, J = 14.8 Hz, 2H), 3.14 (dd, J = 12.8, 6.0 Hz, 1H), 2.72 (dd, J = 12.8, 8.8 Hz, 1H), 2.13−2.08 (m, 1H), 1.64−1.60 (m, 1H), 1.17−1.12 (m, 1H), 1.09−1.04 (m, 1H). HRMS calcd for $C_{15}H_{17}FNO_2^+$ ([M + H]$^+$): 262.1238; found, 262.1227. $[\alpha]_D^{20}$ +57.2 (c 0.1, MeOH).

(−)-(2-(5-((2-Methylallyl)oxy)benzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-7i). ^{1}H NMR (CD_3OD) δ 7.71 (d, J = 2.0 Hz, 1H), 7.28 (d, J = 8.8 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 2.0 Hz, 1H), 5.14 (s, 1H), 5.01 (s, 1H), 4.53 (s, 2H), 3.32 (dd, J = 12.8, 6.0 Hz, 1H), 2.88 (dd, J = 12.8, 8.8 Hz, 1H), 2.17−2.11 (m, 1H), 1.88 (s, 3H), 1.62−1.58 (m, 1H), 1.34−1.29 (m, 1H), 1.15−1.10 (m, 1H); ^{13}C NMR (CD_3OD) δ 154.9, 151.7, 147.3, 143.2, 129.2, 121.8, 113.1, 112.0, 110.6, 106.4, 74.6, 45.5, 19.9, 18.6, 17.8, 13.3. HRMS calcd for $C_{16}H_{20}NO_2^+$ ([M + H]$^+$): 258.1489; found, 258.1477. $[\alpha]_D^{20}$ −82.5 (c 0.15, MeOH).

(+)-(2-(5-((2-Methylallyl)oxy)benzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-7i). ^{1}H NMR (CD_3OD) δ 7.71 (d, J = 2.4 Hz, 1H), 7.29 (d, J = 8.8 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 2.4 Hz, 1H), 5.14 (s, 1H), 5.01 (s, 1H), 4.53 (s, 2H), 3.32 (dd, J = 12.8, 6.0 Hz, 1H), 2.88 (dd, J = 12.8, 8.8 Hz, 1H), 2.17−2.11 (m, 1H), 1.88 (s, 3H), 1.62−1.57 (m, 1H), 1.34−1.29 (m, 1H), 1.15−1.09 (m, 1H). HRMS calcd for $C_{16}H_{20}NO_2^+$ ([M + H]$^+$): 258.1489; found, 258.1477. $[\alpha]_D^{20}$ +63.4 (c 0.15, MeOH).

(−)-(2-(2-Ethyl-5-methoxybenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-8a). ^{1}H NMR (CD_3OD) δ 7.20 (d, J = 9.2 Hz, 1H), 6.86 (d, J = 9.2 Hz, 1H), 6.50 (s, 1H), 3.88 (s, 3H), 3.15 (dd, J = 13.2, 7.2 Hz, 1H), 2.95 (dd, J = 12.8, 8.4 Hz, 1H), 2.76 (q, J = 7.6 Hz, 2H), 2.01−1.98 (m, 1H), 1.43−1.41 (m, 1H), 1.32 (t, J = 7.6 Hz, 3H), 1.25−1.21 (m, 1H), 1.10−1.07 (m, 1H); ^{13}C NMR ($CDCl_3$) δ 163.2, 155.7, 151.3, 130.9, 120.3, 109.9, 108.5, 100.9, 57.0, 45.7, 22.9, 18.6, 17.3, 12.9, 12.5. HRMS calcd for $C_{15}H_{20}NO_2^+$ ([M + H]$^+$): 246.1489; found, 246.1477. $[\alpha]_D^{20}$ −71.2 (c 0.5, MeOH).

(+)-(2-(2-Ethyl-5-methoxybenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-8a). ^{1}H NMR (CD_3OD) δ 7.21 (d, J = 9.2 Hz, 1H), 6.87 (d, J = 9.2 Hz, 1H), 6.50 (s, 1H), 3.88 (s, 3H), 3.15 (dd, J = 12.8, 6.8 Hz, 1H), 2.95 (dd, J = 12.8, 8.0 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 2.01−1.98 (m, 1H), 1.42−1.40 (m, 1H), 1.32 (t, J = 7.6 Hz, 3H), 1.26−1.21 (m, 1H), 1.10−1.06 (m, 1H). HRMS calcd for $C_{15}H_{20}NO_2^+$ ([M + H]$^+$): 246.1489; found, 246.1481. $[\alpha]_D^{20}$ +78.7 (c 0.15, MeOH).

(−)-(2-(5-Ethoxy-2-ethylbenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-8b). ^{1}H NMR (CD_3OD) δ 7.18 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 8.8 Hz, 1H), 6.50 (s, 1H), 4.13−4.05 (m, 2H), 3.21 (dd, J = 13.2, 7.6 Hz, 1H), 2.95 (dd, J = 12.8, 8.0 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 2.05−2.03 (m, 1H), 1.53−1.51 (m, 1H), 1.45 (t, J = 6.8 Hz, 3H), 1.32 (t, J = 7.6 Hz, 3H), 1.29−1.26 (m, 1H), 1.11−1.07 (m, 1H); ^{13}C NMR (CD_3OD) δ 163.1, 154.8, 151.3, 130.7, 120.8, 110.1, 109.9, 100.9, 66.3, 45.6, 22.9, 18.6, 17.6, 15.6, 13.1, 12.5. HRMS calcd for $C_{16}H_{22}NO_2^+$ ([M + H]$^+$): 260.1645; found, 260.1639. $[\alpha]_D^{20}$ −57.0 (c 0.2, MeOH).

(+)-(2-(5-Ethoxy-2-ethylbenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-8b). ^{1}H NMR (CD_3OD) δ 7.18 (d, J = 8.8 Hz, 1H), 6.85 (d, J = 8.8 Hz, 1H), 6.50 (s, 1H), 4.14−4.05 (m, 2H), 3.20 (dd, J = 13.2, 7.6 Hz, 1H), 2.95 (dd, J = 12.8, 8.0 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 2.05−2.02 (m, 1H), 1.53−1.51 (m, 1H), 1.45 (t, J = 6.8 Hz, 3H), 1.32 (t, J = 7.6 Hz, 3H), 1.29−1.25 (m, 1H), 1.11−1.06 (m, 1H). HRMS calcd for $C_{16}H_{22}NO_2^+$ ([M + H]$^+$): 260.1645; found, 260.1643. $[\alpha]_D^{20}$ +66.0 (c 0.1, MeOH).

(−)-(2-(2-Ethyl-5-propoxybenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-8c). ^{1}H NMR (CD_3OD) δ 7.17 (d, J = 8.8 Hz, 1H), 6.84 (d, J = 8.8 Hz, 1H), 6.50 (s, 1H), 4.01−3.94 (m, 2H), 3.30 (dd, J = 12.8, 7.6 Hz, 1H), 2.86 (dd, J = 12.8, 8.8 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 2.07−2.05 (m, 1H), 1.89−1.83 (m, 2H), 1.59−1.54 (m, 1H), 1.34−1.27 (m, 4H), 1.11−1.06 (m, 4H); ^{13}C NMR (CD_3OD) δ 163.1, 155.0, 151.3, 130.6, 120.8, 110.2, 109.8, 100.9, 72.4, 45.6, 24.2, 22.9, 18.5, 17.8, 13.2, 12.5, 11.2. HRMS calcd for $C_{17}H_{24}NO_2^+$ ([M + H]$^+$): 274.1802; found, 274.1789. $[\alpha]_D^{20}$ −66.5 (c 0.1, MeOH).

(+)-(2-(2-Ethyl-5-propoxybenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-8c). ^{1}H NMR (CD_3OD) δ 7.17 (d, J = 8.8 Hz, 1H), 6.84 (d, J = 8.8 Hz, 1H), 6.50 (s, 1H), 4.01−3.94 (m, 2H), 3.30 (dd, J = 12.8, 7.6 Hz, 1H), 2.86 (dd, J = 12.8, 8.8 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 2.07−2.04 (m, 1H), 1.89−1.83 (m, 2H), 1.59−1.54 (m, 1H), 1.34−1.26 (m, 4H), 1.11−1.06 (m, 4H). HRMS calcd for $C_{17}H_{24}NO_2^+$ ([M + H]$^+$): 274.1802; found, 274.1796. $[\alpha]_D^{20}$ +68.7 (c 0.1, MeOH).

(−)-(2-(2-Ethyl-5-(2-fluoroethoxy)benzofuran-4-yl)-cyclopropyl)methanamine Hydrochloride ((−)-8d). ^{1}H NMR (CD_3OD) δ 7.21 (d, J = 8.8 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 6.53 (s, 1H), 4.89−4.87 (m, 1H), 4.77−4.74 (m, 1H), 4.34−4.23 (m, 2H), 3.18 (dd, J = 12.8, 7.2 Hz, 1H), 2.98 (dd, J = 12.8, 8.0 Hz, 1H), 2.78 (q, J = 7.6 Hz, 2H), 2.07−2.04 (m, 1H), 1.49−1.46 (m, 1H), 1.35−1.28 (m, 4H), 1.12−1.09 (m, 1H). HRMS calcd for $C_{16}H_{21}FNO_2^+$ ([M + H]$^+$): 278.1551; found, 278.1563. $[\alpha]_D^{20}$ −118.0 (c 0.1, MeOH).

(+)-(2-(2-Ethyl-5-(2-fluoroethoxy)benzofuran-4-yl)-cyclopropyl)methanamine Hydrochloride ((+)-8d). ^{1}H NMR (CD_3OD) δ 7.21 (d, J = 8.8 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 6.53 (s, 1H), 4.89−4.87 (m, 1H), 4.77−4.74 (m, 1H), 4.34−4.23 (m, 2H), 3.18 (dd, J = 12.8, 7.2 Hz, 1H), 2.98 (dd, J = 12.8, 8.0 Hz, 1H), 2.78 (q, J = 7.6 Hz, 2H), 2.07−2.04 (m, 1H), 1.49−1.46 (m, 1H), 1.35−1.28 (m, 4H), 1.12−1.09 (m, 1H); ^{13}C NMR (CD_3OD) δ 163.4, 154.6, 151.6, 131.0, 121.3, 110.3, 110.1, 101.0, 83.9 (d, J_{CF} = 166.4 Hz), 70.3 (d, J_{CF} = 18.7 Hz), 45.5, 22.9, 18.8, 17.4, 12.9, 12.5. HRMS calcd for $C_{16}H_{21}FNO_2^+$ ([M + H]$^+$): 278.1551; found, 278.1549. $[\alpha]_D^{20}$ +113.5 (c 0.1, MeOH).

(−)-(2-(5-(Allyloxy)-2-ethylbenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((−)-8e). ^{1}H NMR (CD_3OD) δ 7.18 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 8.8 Hz, 1H), 6.51 (s, 1H), 6.21−6.11 (m, 1H), 5.46 (dd, J = 15.6, 1.6 Hz, 1H), 5.30 (dd, J = 10.4, 1.6 Hz, 1H), 4.60 (d, J = 5.6 Hz, 2H), 3.18 (dd, J = 13.2, 6.8 Hz, 1H), 2.96 (dd, J = 13.2, 8.0 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 2.09−2.05 (m, 1H), 1.53−1.50 (m, 1H), 1.32 (t, J = 7.6 Hz, 3H), 1.29−1.27 (m, 1H), 1.12−1.08 (m, 1H); ^{13}C NMR (CD_3OD) δ 163.2, 154.6, 151.5, 135.6, 130.7, 121.0, 118.3, 110.6, 109.9, 101.0, 71.8, 45.6, 22.9, 18.6, 17.6, 13.1, 12.5. HRMS calcd for $C_{17}H_{22}NO_2^+$ ([M + H]$^+$): 272.1645; found, 272.1635. $[\alpha]_D^{20}$ −92.5 (c 0.2, MeOH).

(+)-(2-(5-(Allyloxy)-2-ethylbenzofuran-4-yl)cyclopropyl)-methanamine Hydrochloride ((+)-8e). ^{1}H NMR (CD_3OD) δ 7.18 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 8.8 Hz, 1H), 6.51 (s, 1H), 6.21−6.11 (m, 1H), 5.46 (dd, J = 15.6, 1.6 Hz, 1H), 5.30 (dd, J = 10.4, 1.6 Hz, 1H), 4.60 (d, J = 5.6 Hz, 2H), 3.19 (dd, J = 13.2, 6.8 Hz, 1H), 2.98 (dd, J = 13.2, 8.0 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 2.07−2.03 (m, 1H), 1.53−1.50 (m, 1H), 1.32 (t, J = 7.6 Hz, 3H), 1.29−1.26 (m, 1H), 1.12−1.07 (m, 1H). HRMS calcd for $C_{17}H_{22}NO_2^+$ ([M + H]$^+$): 272.1645; found, 272.1640. $[\alpha]_D^{20}$ +107.6 (c 0.05, MeOH).

(−)-(2-(5-(Cyclopropylmethoxy)-2-ethylbenzofuran-4-yl)-cyclopropyl)methanamine Hydrochloride ((−)-8f). ^{1}H NMR (CD_3OD) δ 7.17 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 8.8 Hz, 1H), 6.51 (s, 1H), 3.87 (d, J = 7.2 Hz, 2H), 3.19 (dd, J = 12.8, 7.2 Hz, 1H), 3.01 (dd, J = 12.8, 7.6 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 2.07−2.05 (m, 1H), 1.51−1.48 (m, 1H), 1.36−1.29 (m, 5H), 1.13−1.10 (m, 1H), 0.68−0.64 (m, 2H), 0.43−0.40 (m, 2H); ^{13}C NMR (CD_3OD) δ 163.2, 155.0, 151.4, 130.7, 120.9, 110.3, 109.9, 100.9, 75.8, 45.7, 22.9, 18.8, 17.6, 13.0, 12.5, 11.6, 4.0, 3.7. HRMS calcd for $C_{18}H_{24}NO_2^+$ ([M + H]$^+$): 286.1802; found, 286.1788. $[\alpha]_D^{20}$ −92.5 (c 0.2, MeOH).

(+)-(2-(5-(Cyclopropylmethoxy)-2-ethylbenzofuran-4-yl)-cyclopropyl)methanamine Hydrochloride ((+)-8f). ^{1}H NMR (CD_3OD) δ 7.17 (d, J = 8.8 Hz, 1H), 6.83 (d, J = 8.8 Hz, 1H), 6.51 (s, 1H), 3.88 (d, J = 7.2 Hz, 2H), 3.19 (dd, J = 13.2, 7.2 Hz, 1H), 3.02 (dd, J = 12.8, 8.0 Hz, 1H), 2.77 (q, J = 7.6 Hz, 2H), 2.08−2.03 (m, 1H), 1.51−1.47 (m, 1H), 1.34−1.30 (m, 5H), 1.13−1.08 (m, 1H), 0.67−0.63 (m, 2H), 0.42−0.39 (m, 2H). HRMS calcd for $C_{18}H_{24}NO_2^+$ ([M + H]$^+$): 286.1802; found, 286.1789. $[\alpha]_D^{20}$ +98.8 (c 0.1, MeOH).

Calcium Flux Assay. Calcium flux assays were performed with Flp-In-293 cells stably expressing the human 5-HT$_{2A}$, 5-HT$_{2B}$, or 5-HT$_{2C\text{-}INI}$ using a FLIPR^{TETRA} fluorescence imaging plate reader (Molecular Dynamics) as previously described.[9] Briefly, cells were seeded in 384-well poly-L-lysine plates at a density of 10 000 cells/well, and next day, cells were loaded with Fluo-4 Direct dye (Invitrogen, 20

μL/well) for 1 h at 37 °C in drug buffer (1× HBSS, 2.5 mM probenecid, and 20 mM HEPES, pH 7.4). Drug dilutions were prepared at 3× final concentration in drug buffer (1× HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4), 10 μL per well of drug was added, and calcium flux was measured (1 read/s) for 300 s. For experiments to determine bias, drug solutions used for FLIPR assay were exactly the same as used for the Tango assay. Compounds were routinely tested at concentrations from 1 pM up to 10 μM, but in the cases of weak potency, compounds were retested up to at least 100 μM. Fluorescence in each well was normalized to the average of the first 10 reads (i.e., baseline fluorescence), and then the maximum-fold increase was determined and fold over baseline was plotted as a function of drug concentration. Data were normalized to % 5-HT stimulation and analyzed using log(agonist) vs response in Graphpad Prism 5.0.

Tango Arrestin Recruitment Assay. The Tango assay measuring β-arrestin-2 recruitment utilizes an HEK cell line expressing TEV fused-β-arrestin2 (HTLA cells, kindly provided by Dr. Richard Axel) and a tetracycline transactivator (tTA)-driven luciferase. HTLA cells are transfected with the 5-HT_{2C} INI receptor fused to tTA containing a TEV cleavage site. Cells were plated exactly like for the FLIPR assay in a 40 μL volume except into white 384-well plates and stimulated with the exact same drugs used for FLIPR (3×, 20 μL per well in HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4). After 20 h of incubation at 37 °C and 5% CO_2, medium containing drugs was decanted and 20 μL of Bright-Glo reagent was added per well (Promega). The plate was incubated for 20 min at room temperature for complete cell lysis before being counted using a Wallac MicroBeta Trilux luminescence counter (PerkinElmer). Results (relative luminescence units) were plotted as a function of drug concentration, normalized to % 5-HT, and subjected to nonlinear least-squares regression analysis using the sigmoidal dose−response function in GraphPad Prism 5.0.

Desensitization Assays. For calcium flux assays measuring desensitization, Flp-In-293 cells expressing the 5-HT_{2C} INI receptor were plated exactly as described for the FLIPR assay. First, addition of drug was initiated by decanting the medium and adding 20 μL per well of drug buffer (HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4). Cells were then pretreated with 10 μL per well of varying concentrations of drugs (3×) and allowed to incubate for 30 min at 37 °C. Afterward drugs were decanted and cells were washed three times with 20 μL per well of drug buffer. Dye was applied as previously described, and cells were incubated for an additional 30 min. Cells were then challenged with varying concentrations of agonist to measure calcium flux as previously described.[9,25]

For PI hydrolysis assays measuring time-dependent desensitization, Flp-In-293 5-HT_{2C} INI cells were plated into 96-well poly-L-lysine coated plates at 25 000 cells per well in inositol-free DMEM containing 2 μCi/well of [^{3}H]myo-inositol. After labeling with [^{3}H]myo-inositol for 16−18 h, the medium was decanted and cells were washed twice with inositol-free DMEM and 200 μL of inositol-free DMEM was added per well. Drugs (5×) at varying concentrations were diluted in drug buffer (HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4), and 50 μL was added per well and incubated for indicated time points. Exactly 2 h before lysing, 10 μL of LiCl (15 mM final concentration) was added to each well. After indicated time points, the medium was decanted and 50 μL of cold 50 mM formic acid was added to lyse cells. Plates were incubated at 4 °C overnight and next day, 10 μL of lysate was added to 75 μL of 0.2 mg/mL RNA binding yttrium silicate beads (PerkinElmer). Plates containing lysate and beads were incubated for 1 h on a shaker, centrifuged at 300*g* for 1 min, and counted using a Wallac MicroBeta Trilux plate reader (PerkinElmer). Data were plotted (CPM) and analyzed in GraphPad Prism 5.0.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.6b01194.

Synthetic procedures, chiral separation methods, and characterization data of all intermediates; asymmetric synthesis of compound **39**/(+)-**6d**; methods and results of selected compounds in the binding and MT_1, MT_2 assays (PDF)

Molecular formula strings and some data (CSV)

■ AUTHOR INFORMATION

Corresponding Authors

*B.L.R.: e-mail, bryan_roth@med.unc.edu; telephone, +1 919-966-7535; fax, 919-843-5788.

*A.P.K.: e-mail, kozikowa@uic.edu; telephone, +1 312 996-7577; fax, 312-996-7107.

Present Addresses

[⊥]J.C.: iHuman Institute, ShanghaiTech University, 99 Haike Road, Pudong New District, Shanghai 201210, China.

[#]P.M.G.: Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.

[▽]H.Z.: Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, MD 20850, United States.

Author Contributions

[‖]J.C., J.D.M., and P.M.G contributed equally.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Financial support from the National Institute of Mental Health (NIMH) (Grant R01MH99993) and Psychoactive Drug Screening Program (PDSP, Contract HHSN-271-2013-00017-C) is gratefully acknowledged.

■ ABBREVIATIONS USED

5-HT, serotonin; CNS, central nervous system; FDA, U.S. Food and Drug Administration; FLIPR, fluorescence imaging plate reader; GPCR, G protein-coupled receptor; HEK-293, human embryonic kidney-293 cell; HPLC, high-performance liquid chromatography; HTS, high throughput screening; IP, inositol phosphate; MT, melatonin; PI, phosphoinositide

■ REFERENCES

(1) Nilsson, B. M. 5-Hydroxytryptamine 2C (5-HT_{2C}) Receptor Agonists as Potential Antiobesity Agents. *J. Med. Chem.* **2006**, *49*, 4023−4034.

(2) Rosenzweig-Lipson, S.; Comery, T. A.; Marquis, K. L.; Gross, J.; Dunlop, J. 5-HT_{2C} Agonists as Therapeutics for the Treatment of Schizophrenia. *Handb. Exp. Pharmacol.* **2012**, *213*, 147−165.

(3) Higgins, G. A.; Sellers, E. M.; Fletcher, P. J. From Obesity to Substance Abuse: Therapeutic Opportunities for 5-HT_{2C} Receptor Agonists. *Trends Pharmacol. Sci.* **2013**, *34*, 560−570.

(4) Berger, M.; Gray, J. A.; Roth, B. L. The Expanded Biology of Serotonin. *Annu. Rev. Med.* **2009**, *60*, 355−366.

(5) Nichols, D. E.; Nichols, C. D. Serotonin Receptors. *Chem. Rev.* **2008**, *108*, 1614−1641.

(6) Pandi-Perumal, S. R.; Trakht, I.; Srinivasan, V.; Spence, D. W.; Maestroni, G. J.; Zisapel, N.; Cardinali, D. P. Physiological Effects of

Melatonin: Role of Melatonin Receptors and Signal Transduction Pathways. *Prog. Neurobiol.* **2008**, *85*, 335−353.
(7) Prosser, R. A. Melatonin Inhibits in vitro Serotonergic Phase Shifts of the Suprachiasmatic Circadian Clock. *Brain Res.* **1999**, *818*, 408−413.
(8) Millan, M. J.; Marin, P.; Kamal, M.; Jockers, R.; Chanrion, B.; Labasque, M.; Bockaert, J.; Mannoury la Cour, C. The Melatonergic Agonist and Clinically Active Antidepressant, Agomelatine, Is a Neutral Antagonist at 5-HT_{2C} Receptors. *Int. J. Neuropsychopharmacol.* **2011**, *14*, 768−783.
(9) Cheng, J.; Giguere, P. M.; Onajole, O. K.; Lv, W.; Gaisin, A.; Gunosewoyo, H.; Schmerberg, C. M.; Pogorelov, V. M.; Rodriguiz, R. M.; Vistoli, G.; Wetsel, W. C.; Roth, B. L.; Kozikowski, A. P. Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents. *J. Med. Chem.* **2015**, *58*, 1992−2002.
(10) Cheng, J. J.; Kozikowski, A. P. We Need 2C but Not 2B: Developing Serotonin 2C (5-HT_{2C}) Receptor Agonists for the Treatment of CNS Disorders. *ChemMedChem* **2015**, *10*, 1963−1967.
(11) Halberstadt, A. L. Recent Advances in the Neuropsychopharmacology of Serotonergic Hallucinogens. *Behav. Brain Res.* **2015**, *277*, 99−120.
(12) Roth, B. L. Drugs and Valvular Heart Disease. *N. Engl. J. Med.* **2007**, *356*, 6−9.
(13) Hutcheson, J. D.; Setola, V.; Roth, B. L.; Merryman, W. D. Serotonin Receptors and Heart Valve Disease–It Was Meant 2B. *Pharmacol. Ther.* **2011**, *132*, 146−157.
(14) Cho, S. J.; Jensen, N. H.; Kurome, T.; Kadari, S.; Manzano, M. L.; Malberg, J. E.; Caldarone, B.; Roth, B. L.; Kozikowski, A. P. Selective 5-Hydroxytryptamine 2C Receptor Agonists Derived from the Lead Compound Tranylcypromine: Identification of Drugs with Antidepressant-Like Action. *J. Med. Chem.* **2009**, *52*, 1885−1902.
(15) Johnsa, J. D.; Neville, M. W. Tasimelteon: a Melatonin Receptor Agonist for Non-24-h Sleep-Wake Disorder. *Ann. Pharmacother.* **2014**, *48*, 1636−1641.
(16) Chambers, J. J.; Parrish, J. C.; Jensen, N. H.; Kurrasch-Orbaugh, D. M.; Marona-Lewicka, D.; Nichols, D. E. Synthesis and Pharmacological Characterization of a Series of Geometrically Constrained 5-$HT_{2A/2C}$ Receptor Ligands. *J. Med. Chem.* **2003**, *46*, 3526−3535.
(17) Kenakin, T.; Watson, C.; Muniz-Medina, V.; Christopoulos, A.; Novick, S. A Simple Method for Quantifying Functional Selectivity and Agonist Bias. *ACS Chem. Neurosci.* **2012**, *3*, 193−203.
(18) Allen, J. A.; Yost, J. M.; Setola, V.; Chen, X.; Sassano, M. F.; Chen, M.; Peterson, S.; Yadav, P. N.; Huang, X. P.; Feng, B.; Jensen, N. H.; Che, X.; Bai, X.; Frye, S. V.; Wetsel, W. C.; Caron, M. G.; Javitch, J. A.; Roth, B. L.; Jin, J. Discovery of β-Arrestin-Biased Dopamine D_2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. *Proc. Natl. Acad. Sci. U. S. A.* **2011**, *108*, 18488−18493.
(19) White, K. L.; Scopton, A. P.; Rives, M. L.; Bikbulatov, R. V.; Polepally, P. R.; Brown, P. J.; Kenakin, T.; Javitch, J. A.; Zjawiony, J. K.; Roth, B. L. Identification of Novel Functionally Selective κ-Opioid Receptor Scaffolds. *Mol. Pharmacol.* **2014**, *85*, 83−90.
(20) Manglik, A.; Lin, H.; Aryal, D. K.; McCorvy, J. D.; Dengler, D.; Corder, G.; Levit, A.; Kling, R. C.; Bernat, V.; Hübner, H.; Huang, X.-P.; Sassano, M. F.; Giguere, P. M.; Löber, S.; Duan, D.; Scherrer, G.; Kobilka, B. K.; Gmeiner, P.; Roth, B. L.; Shoichet, B. K. Structure-Based Discovery of Opioid Analgesics with Reduced Side Effects. *Nature* **2016**, *537*, 185−190.
(21) McCorvy, J. D.; Roth, B. L. Structure and Function of Serotonin G Protein-Coupled Receptors. *Pharmacol. Ther.* **2015**, *150*, 129−142.
(22) Luttrell, L. M.; Lefkowitz, R. J. The Role of β-Arrestins in the Termination and Transduction of G-Protein-Coupled Receptor Signals. *J. Cell Sci.* **2002**, *115*, 455−465.
(23) Chen, G.; Cho, S. J.; Huang, X. P.; Jensen, N. H.; Svennebring, A.; Sassano, M. F.; Roth, B. L.; Kozikowski, A. P. Rational Drug Design Leading to the Identification of a Potent 5-HT_{2C} Agonist Lacking 5-HT_{2B} Activity. *ACS Med. Chem. Lett.* **2011**, *2*, 929−932.
(24) Cheng, J. J.; Giguere, P. M.; Lv, W.; Roth, B. L.; Kozikowski, A. P. Design and Synthesis of (2-(5-Chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)cyclopropyl)methanamine as a Selective Serotonin 2C Agonist. *Tetrahedron Lett.* **2015**, *56*, 3420−3422.
(25) Cheng, J.; Giguere, P. M.; Schmerberg, C. M.; Pogorelov, V. M.; Rodriguiz, R. M.; Huang, X.-P.; Zhu, H.; McCorvy, J. D.; Wetsel, W. C.; Roth, B. L.; Kozikowski, A. P. Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. *J. Med. Chem.* **2016**, *59*, 578−591.
(26) Buccini, M.; Piggott, M. J. A Four-Step Total Synthesis of Radermachol. *Org. Lett.* **2014**, *16*, 2490−2493.
(27) Li, H.; Pu, S. Z.; Liu, G.; Chen, B. Photochromism of New Diarylethene Derivatives Based on the Hybrid Photochromic Skeleton of Benzofuran and Benzene Moieties. *Dyes Pigm.* **2014**, *101*, 15−24.
(28) Vallgarda, J.; Hacksell, U. Stereoselective Palladium-Catalyzed Cyclopropanation of α,β-Unsaturated Carboxylic Acids Derivatized with Oppolzer Sultam. *Tetrahedron Lett.* **1991**, *32*, 5625−5628.
(29) Chen, J. Y.; Levant, B.; Jiang, C.; Keck, T. M.; Newman, A. H.; Wang, S. M. Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D_3 Receptor Antagonists. *J. Med. Chem.* **2014**, *57*, 4962−4968.
(30) Vallgarda, J.; Appelberg, U.; Arvidsson, L. E.; Hjorth, S.; Svensson, B. E.; Hacksell, U. trans-2-Aryl-*N*,*N*-dipropylcyclopropylamines: Synthesis and Interactions with 5-HT_{1A} Receptors. *J. Med. Chem.* **1996**, *39*, 1485−1493.
(31) Zlotos, D. P.; Jockers, R.; Cecon, E.; Rivara, S.; Witt-Enderby, P. A. MT_1 and MT_2 Melatonin Receptors: Ligands, Models, Oligomers, and Therapeutic Potential. *J. Med. Chem.* **2014**, *57*, 3161−3185.
(32) Kroeze, W. K.; Sassano, M. F.; Huang, X. P.; Lansu, K.; McCorvy, J. D.; Giguere, P. M.; Sciaky, N.; Roth, B. L. PRESTO-Tango as an Open-Source Resource for Interrogation of the Druggable Human GPCRome. *Nat. Struct. Mol. Biol.* **2015**, *22*, 362−369.
(33) Kenakin, T. Quantifying Biased β-Arrestin Signaling. *Handb. Exp. Pharmacol.* **2014**, *219*, 57−83.
(34) Berg, K. A.; Stout, B. D.; Maayani, S.; Clarke, W. P. Differences in Rapid Desensitization of 5-Hydroxytryptamine$_{2A}$ and 5-Hydroxytryptamine$_{2C}$ Receptor-Mediated Phospholipase C Activation. *J. Pharmacol. Exp. Ther.* **2001**, *299*, 593−602.
(35) Barker, E. L.; Westphal, R. S.; Schmidt, D.; Sandersbush, E. Constitutively Active 5-Hydroxytryptamine$_{2C}$ Receptors Reveal Novel Inverse Agonist Activity of Receptor Ligands. *J. Biol. Chem.* **1994**, *269*, 11687−11690.
(36) Niswender, C. M.; Copeland, S. C.; Herrick-Davis, K.; Emeson, R. B.; Sanders-Bush, E. RNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity. *J. Biol. Chem.* **1999**, *274*, 9472−9478.